<SEC-DOCUMENT>0001213900-16-017124.txt : 20160929
<SEC-HEADER>0001213900-16-017124.hdr.sgml : 20160929
<ACCEPTANCE-DATETIME>20160929084530
ACCESSION NUMBER:		0001213900-16-017124
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20160928
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160929
DATE AS OF CHANGE:		20160929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		161908374

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k092816_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d) of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): September 28, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></td>
    <TD STYLE="width: 2%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-52446</B></FONT></td>
    <TD STYLE="width: 2%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>74-2963609</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
        or other jurisdiction</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of&nbsp;incorporation)</FONT></P></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
        Number)</FONT></P></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
        Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        No.)</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>275
        Madison Avenue, 7th Floor</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
        York, NY</B></FONT></P></td>
    <TD STYLE="vertical-align: top; width: 2%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10016</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: <B>(646) 677-3875</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
    name or former address, if changed since last report)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<U>see</U> General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></td>
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&#9744;</td>
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&#9744;</td>
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&#9744;</td>
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;1.01.
Entry into a Material Definitive Agreement. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 29, 2016, Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) entered into an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;) with H.C. Wainwright
&amp; Co. as representative (the &ldquo;Representative&rdquo;) of the several underwriters party thereto (collectively, the &ldquo;Underwriters&rdquo;),
relating to the public offering (the &ldquo;Offering&rdquo;) of 8,000,000 shares of the Company&rsquo;s common stock, $0.001 par
value per share (the &ldquo;Firm Shares&rdquo;), at a price to the public of $1.25 per share (the &ldquo;Offering Price&rdquo;),
less underwriting discounts. Under the terms of the Underwriting Agreement, the Company has also granted the Underwriters a 30-day
option to purchase up to an additional 1,200,000 shares of Common Stock (the &ldquo;Option Shares&rdquo; and, together with the
Firm Shares, the &ldquo;Shares&rdquo;) to cover over-allotments, if any, at the Offering Price. The net proceeds to the Company
from the sale of the Shares, after deducting the underwriting discounts and other estimated offering expenses payable by the Company,
are expected to be approximately $9,255,000 million assuming no exercise by the Underwriters of their over-allotment option for
the Option Shares, or $10,665,000 million if the Underwriters exercise their over-allotment option for the Option Shares in full.
The Offering is expected to close on October 4, 2016, subject to the satisfaction of customary closing conditions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Offering is being made pursuant to the Company&rsquo;s effective registration statement on Form S-3 (File No.&nbsp;333-194768)
filed with the Securities and Exchange Commission on March&nbsp;24, 2014, and declared effective on April&nbsp;17, 2014, and the
related preliminary prospectus supplement and prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as
amended, other obligations of the parties, and termination provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Underwriting Agreement, subject to certain exceptions, the Company and its directors and officers have agreed not to sell
or otherwise dispose of any of the Company&rsquo;s securities held by them for a period ending 90 days after the date of the final
prospectus supplement relating to the Offering without first obtaining the written consent of the Representative.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing is only a brief description of the material terms of the Underwriting Agreement, does not purport to be a complete description
of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the Underwriting Agreement
that is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement has been attached hereto as an exhibit to provide investors and security holders with information regarding
its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and
covenants contained in the Underwriting Agreement were made only for purposes of the Underwriting Agreement and as of specific
dates, were solely for the benefit of the parties to the Underwriting Agreement, and may be subject to limitations agreed upon
by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection
with the execution of the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal opinion of The Matt Law Firm, PLLC relating to the Common Stock being offered is filed as Exhibit 5.1 to this Current Report
on Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01.&#9;Regulation FD Disclosure. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 28, 2016, the Company issued a press release announcing that it intended to make a public offering of shares of its
common stock. On September 29, 2016, the Company issued a press release announcing the pricing and terms of the Offering. Copies
of the two press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are each incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including
Exhibits 99.1 and 99.2 and information set forth therein, is deemed to have been furnished and shall not be deemed to be &ldquo;filed&rdquo;
under the Securities Exchange Act of 1934.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item&nbsp;9.01</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial Statements and Exhibits.</B>&nbsp;<B></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the rules and regulations of the Securities and Exchange Commission, the attached exhibits are deemed to have been filed with
the Securities and Exchange Commission:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; width: 91%; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    Agreement, dated as of September 29, 2016,&nbsp;by and between Actinium Pharmaceuticals, Inc. and H.C. Wainwright &amp; Co.
    as representative of the several underwriters party thereto.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of The Matt Law Firm, PLLC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of The Matt Law Firm, PLLC (included in Exhibit 5.1).</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
    Release issued by Actinium Pharmaceuticals, Inc. dated September 28, 2016. &nbsp; &nbsp; &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
    Release issued by Actinium Pharmaceuticals, Inc. dated September 29, 2016.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;&nbsp;September
    29, 2016</FONT></td>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
    PHARMACEUTICALS, INC.</B></FONT></td>
    </tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 60%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 36%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    </tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></td>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sandesh Seth&nbsp;</I></FONT></td>
    </tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;Sandesh
        Seth</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;
        &nbsp;Executive Chairman</FONT></P></td>
    </tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">4</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>f8k092816ex1i_actinium.htm
<DESCRIPTION>UNDERWRITING AGREEMENT, DATED AS OF SEPTEMBER 28, 2016, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND H.C. WAINWRIGHT & CO. AS REPRESENTATIVE OF THE SEVERAL UNDERWRITERS PARTY THERETO.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACTINIUM
PHARMACEUTICALS, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">8,000,000 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">($0.001
par value)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
29, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Representative of the several Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">named
in <U>Schedule A</U> hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">430
Park Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), confirms its agreement pursuant to
this Underwriting Agreement (this &ldquo;<B><I>Agreement</I></B>&rdquo;) to the several underwriters listed on <U>Schedule
A</U> attached hereto (collectively, the &ldquo;<B><I>Underwriters</I></B>&rdquo;), for whom H.C. Wainwright &amp; Co., LLC
is acting as representative (in such capacity, the &ldquo;<B><I>Representative</I></B>&rdquo;), &nbsp;with respect to the
issue and sale by the Company of an aggregate total of 8,000,000 shares (the &ldquo;<B><I>Firm Shares</I></B>&rdquo;) of the
Company&rsquo;s common stock, $0.001 par value (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), the purchase by the
Underwriters, acting severally and not jointly, of the respective numbers of Firm Shares set forth in <U>Schedule A</U>
hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of the option
described in Section&nbsp;1 hereof to purchase all or any part of   1,200,000 additional shares of Common Stock to cover
over-allotments, if any (the &ldquo;<B><I>Additional Shares</I></B>&rdquo;). The Firm Shares and the Additional Shares are
hereinafter called, collectively, the &ldquo;<B><I>Shares</I></B>.&rdquo;&nbsp; The Shares are described in the Prospectus
which is referred to below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has prepared and filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and
regulations thereunder (collectively, the &ldquo;<B><I>Act</I></B>&rdquo;), with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;)
a registration statement on Form S-3 (File No. 333-194768) under the Act (the &ldquo;<B><I>registration statement</I></B>&rdquo;),
including a prospectus, which registration statement incorporates by reference documents which the Company has filed, or will
file, in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder
(collectively, the &ldquo;<B><I>Exchange Act</I></B>&rdquo;). Such registration statement has become effective under the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
where the context otherwise requires, &ldquo;<B><I>Registration Statement</I></B>,&rdquo; as used herein, means the
registration statement, as amended at the time of such registration statement&rsquo;s effectiveness for purposes of Section
11 of the Act, as such section applies to the respective Underwriters (the &ldquo;<B><I>Effective Time</I></B>&rdquo;),
including (i) all documents filed as a part thereof or incorporated or deemed to be incorporated by reference therein, (ii)
any information contained or incorporated by reference in a prospectus filed with the Commission pursuant to Rule 424(b)
under the Act, to the extent such information is deemed, pursuant to Rule 430A or Rule 430B under the Act, to be part of the
registration statement at the Effective Time and (iii) any registration statement filed to register the offer and sale of
Shares pursuant to Rule 462(b) under the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has furnished to the Representative, for use by the Underwriters and by dealers in connection with the offering of the
Shares, copies of one or more preliminary prospectus supplements and the documents incorporated by reference therein, relating
to the Shares. Except where the context otherwise requires, &ldquo;<B><I>Preliminary Prospectus</I></B>,&rdquo; as used herein,
means each such preliminary prospectus supplement, in the form so furnished, including any basic prospectus (whether or not in
preliminary form) furnished to the Underwriters by the Company and attached to or used with such preliminary prospectus supplement.
Except where the context otherwise requires, &ldquo;<B><I>Basic Prospectus</I></B>,&rdquo; as used herein, means the base prospectus
included as part of the Registration Statement, in the form in which it has most recently been filed with the Commission prior
to the date of this Agreement. Except where the context otherwise requires, &ldquo;<B><I>Prospectus Supplement</I></B>,&rdquo;
as used herein, means the final prospectus supplement, relating to the Shares, filed by the Company with the Commission pursuant
to Rule 424(b) under the Act on or before the second business day after the date hereof (or such earlier time as may be required
under the Act), in the form furnished by the Company to the Underwriters for use by the Underwriters and by dealers in connection
with the offering of the Shares. Except where the context otherwise requires, &ldquo;<B><I>Prospectus</I></B>,&rdquo; as used
herein, means the Basic Prospectus as supplemented by the Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Permitted
Free Writing Prospectuses</I></B>,&rdquo; as used herein, means the documents listed on <U>Schedule B</U> attached hereto and
each &ldquo;road show&rdquo; (as defined in Rule 433 under the Act), if any, related to the offering of the Shares contemplated
hereby that is a &ldquo;written communication&rdquo; (as defined in Rule 405 under the Act). The Underwriters have not offered
or sold and will not offer or sell, without the Company&rsquo;s consent, any Shares by means of any &ldquo;free writing prospectus&rdquo;
(as defined in Rule 405 under the Act) that is required to be filed by the Underwriters with the Commission pursuant to Rule 433
under the Act, other than a Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Covered
Free Writing Prospectuses</I></B>,&rdquo; as used herein, means (i) each &ldquo;issuer free writing prospectus&rdquo; (as defined
in Rule 433(h)(1) under the Act), if any, relating to the Shares, which is not a Permitted Free Writing Prospectus and (ii) each
Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Disclosure
Package</I></B>,&rdquo; as used herein, means the Preliminary Prospectus dated September 28, 2016, as supplemented by the Permitted
Free Writing Prospectuses listed on <U>Schedule B</U> attached hereto, if any, and the information set forth on <U>Schedule C
</U>attached hereto, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Applicable
Time</I></B>&rdquo; as used herein means 7:00 a.m. (Eastern Time) on the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reference herein to the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Prospectus Supplement, the
Prospectus or any Permitted Free Writing Prospectus shall be deemed to refer to and include the documents, if any, incorporated
by reference, or deemed to be incorporated by reference, therein (each, an &ldquo;<B><I>Incorporated Document</I></B>&rdquo; and
collectively, the &ldquo;<B><I>Incorporated Documents</I></B>&rdquo;), including, unless the context otherwise requires, the documents,
if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo;
or &ldquo;supplement&rdquo; with respect to the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the
Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus shall be deemed to refer to and include the filing
of any document under the Exchange Act on or after the initial effective date of the Registration Statement, or the date of the
Basic Prospectus, such Preliminary Prospectus, the Prospectus Supplement, the Prospectus or such Permitted Free Writing Prospectus,
as the case may be, and deemed to be incorporated therein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement, &ldquo;<B><I>business day</I></B>&rdquo; shall mean a day on which NYSE MKT LLC (&ldquo;<B><I>NYSE MKT</I></B>&rdquo;)
is open for trading. The terms &ldquo;herein,&rdquo; &ldquo;hereof,&rdquo; &ldquo;hereto,&rdquo; &ldquo;hereinafter&rdquo; and
similar terms, as used in this Agreement, shall in each case refer to this Agreement as a whole and not to any particular section,
paragraph, sentence or other subdivision of this Agreement. The term &ldquo;or,&rdquo; as used herein, is not exclusive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Underwriters agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sale
and Purchase</U>. Upon the basis of the representations and warranties and subject to the terms and conditions herein set forth,
the Company agrees to sell to the respective Underwriters and each of the Underwriters, severally and not jointly, agrees to purchase
from the Company the respective number of Firm Shares (subject to such adjustment as the Representative may determine to avoid
fractional shares) set forth opposite the name of such Underwriter in <U>Schedule A</U> hereto, subject to adjustment in accordance
herewith, in each case at a purchase price of $1.175 per Share. The Company is advised by the Underwriters that the Underwriters
intend (i) to make a public offering of their respective portions of the Firm Shares as soon after the effectiveness of this Agreement
as in the Underwriters&rsquo; judgment is advisable and (ii) initially to offer the Firm Shares upon the terms set forth in the
Prospectus. The Underwriters may from time to time increase or decrease the public offering price after the initial public offering
to such extent as the Underwriters may determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company hereby grants to the several Underwriters the option to purchase, and upon the basis of the representations
and warranties and subject to the terms and conditions herein set forth, the Underwriters shall have the right to purchase, severally
and not jointly, from the Company, ratably in accordance with the number of Firm Shares to be purchased by each of them, all or
a portion of the Additional Shares as may be necessary to cover over-allotments made in connection with the offering of the Firm
Shares, at the same purchase price per share to be paid by the Underwriters to the Company for the Firm Shares. This option may
be exercised by the Representative on behalf of the Underwriters at any time and from time to time on or before the thirtieth
(30<SUP>th</SUP>) day following the date hereof, by written notice to the Company. Such notice shall set forth the aggregate number
of Additional Shares as to which the option is being exercised, and the date and time when the Additional Shares are to be delivered
(such date and time being herein referred to as the &ldquo;<B><I>Additional Time of Purchase</I></B>&rdquo;); <U>provided</U>,
<U>however</U>, that the Additional Time of Purchase shall not be earlier than the Time of Purchase (as defined below) nor earlier
than the second business day after the date on which the option shall have been exercised nor later than the tenth business day
after the date on which the option shall have been exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
and Delivery</U>. Payment of the purchase price for the Firm Shares shall be made to the Company by Federal Funds wire transfer
against delivery of the Firm Shares to the Representative on behalf of the Underwriters through the facilities of The Depository
Trust Company (&ldquo;<B><I>DTC</I></B>&rdquo;) for the respective accounts of the Underwriters. Such payment and delivery shall
be made at 10:00 a.m., New York time, on October 4, 2016 (the &ldquo;<B><I>Closing Date</I></B>&rdquo;) (unless another time shall
be agreed to by the Representative and the Company). The time at which such payment and delivery are to be made is hereinafter
sometimes called the &ldquo;<B><I>Time of Purchase</I></B>.&rdquo; Electronic transfer of the Firm Shares shall be made to the
Underwriters at the Time of Purchase in such names and in such denominations as the Representative shall specify.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of the purchase price for the Additional Shares shall be made to the Company at the Additional Time of Purchase in the same manner
as the payment for the Firm Shares. Electronic transfer of the Firm Shares shall be made to the Representative for the account
of the Underwriters at the Time of Purchase in such names and in such denominations as the Representative shall specify. The Time
of Purchase and the Additional Time of Purchase are sometimes referred to herein as the Closing Dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deliveries
of the documents described in Section 5 hereof with respect to the purchase of the Shares shall be made at the offices of Lowenstein
Sandler LLP, 1251 Avenue of the Americas, New York, NY 10020, at 10:00 A.M., New York time, on the date of the closing of the
purchase of the Firm Shares or the Additional Shares, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents and warrants to and agrees with each of the Underwriters that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Registration Statement has heretofore become effective under the Act; no stop order of the Commission preventing or suspending
the use of the Basic Prospectus, any Preliminary Prospectus, the Prospectus Supplement, the Prospectus or any Permitted Free Writing
Prospectus, or the effectiveness of the Registration Statement, has been issued, and no proceedings for such purpose have been
instituted or, to the Company&rsquo;s knowledge, are contemplated by the Commission;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Registration Statement complied when it became effective, complies as of the date hereof and, as amended or supplemented, at the
Time of Purchase, each Additional Time of Purchase, if any, and at all times during which a prospectus is required by the Act
to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in connection with
any sale of Shares, will comply, in all material respects, with the requirements of the Act; the conditions to the use of Form
S-3 in connection with the offering and sale of the Shares as contemplated hereby have been satisfied; the Registration Statement
meets, and the offering and sale of the Shares as contemplated hereby comply with, the requirements of Rule 415 under the Act;
the Registration Statement did not, as of the Effective Time, as of the date hereof or as of the Time of Purchase or Additional
Time of Purchase, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading; each Preliminary Prospectus complied, at the time it was filed with
the Commission, and complies as of the date hereof, in all material respects with the requirements of the Act; at no time during
the period that begins on the earlier of the date of such Preliminary Prospectus and the date such Preliminary Prospectus was
filed with the Commission and ends at the later of the Time of Purchase or the last Additional Time of Purchase, if any, did or
will any Preliminary Prospectus, as then amended or supplemented, include an untrue statement of material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading, and at no time during such period did or will any Preliminary Prospectus, as then amended or supplemented, together
with any combination of one or more of the then issued Permitted Free Writing Prospectuses, if any, include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; the Basic Prospectus complied as of its date and the date it was filed with the Commission,
complies as of the date hereof and, as then amended or supplemented, at the Time of Purchase, each Additional Time of Purchase,
if any, and at all times during which a prospectus is required by the Act to be delivered (whether physically or through compliance
with Rule 172 under the Act or any similar rule) in connection with any sale of Shares, will comply, in all material respects,
with the requirements of the Act; at no time during the period that begins on the earlier of the date of such Basic Prospectus
and the date such Basic Prospectus was filed with the Commission and ends at the later of the Time of Purchase or the last Additional
Time of Purchase, if any, did or will any Basic Prospectus, as then amended or supplemented, include an untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, and at no time during such period did or will any Basic Prospectus, as then amended
or supplemented, together with any combination of one or more of the then issued Permitted Free Writing Prospectuses, if any,
include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; the Basic Prospectus furnished to the Underwriters,
as part of any Preliminary Prospectus and the Prospectus, is the same basic prospectus that is included as part of the Registration
Statement, in the form of which has been most recently filed with the Commission, prior to the date of such Preliminary Prospectus
and the Prospectus, respectively; the Disclosure Package as of the Applicable Time does not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; each of the Prospectus Supplement and the Prospectus will comply, as of the date that it
is filed with the Commission and, as then amended or supplemented, the date of the Prospectus Supplement, the Time of Purchase,
each Additional Time of Purchase, if any, and at all times during which a prospectus is required by the Act to be delivered (whether
physically or through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of Shares, in all
material respects, with the requirements of the Act (in the case of the Prospectus, including, without limitation, Section 10(a)
of the Act); at no time during the period that begins on the earlier of the date of the Prospectus Supplement and the date the
Prospectus Supplement is filed with the Commission and ends at the later of the Time of Purchase, the last Additional Time of
Purchase, if any, and the end of the period during which a prospectus is required by the Act to be delivered (whether physically
or through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of Shares did or will any Prospectus
Supplement or the Prospectus, as then amended or supplemented, include an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; each Permitted Free Writing Prospectus does not conflict with the information contained in the Registration Statement,
the Disclosure Package at the Applicable Time or the Prospectus, and at no time during the period that begins on the date of such
Permitted Free Writing Prospectus and ends at the later of the Time of Purchase or the last Additional Time of Purchase, if any,
did or will any Permitted Free Writing Prospectus include an untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
provided, however, that the Company makes no representation or warranty in this Section 3(b) with respect to any statement contained
in the Registration Statement, any Preliminary Prospectus, the Prospectus or any Permitted Free Writing Prospectus in reliance
upon and in conformity with information concerning the Underwriters and furnished in writing by the Representative on behalf of
such Underwriters to the Company expressly for use in the Registration Statement, such Preliminary Prospectus, the Prospectus
or such Permitted Free Writing Prospectus; each Incorporated Document, at the time such document was filed with the Commission
or at the time such document became effective, as applicable, complied, in all material respects, with the requirements of the
Exchange Act and did not include an untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prior
to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any Shares by means of any &ldquo;prospectus&rdquo;
(within the meaning of the Act) or used any &ldquo;prospectus&rdquo; (within the meaning of the Act) in connection with the offer
or sale of the Shares, in each case other than the Disclosure Package and any Permitted Free Writing Prospectus; the Company has
not, directly or indirectly, prepared, used or referred to any Permitted Free Writing Prospectus except in compliance with Rules
164 and 433 under the Act; assuming such Permitted Free Writing Prospectus is so sent or given after the Registration Statement
was filed with the Commission (and after such Permitted Free Writing Prospectus was, if required pursuant to Rule 433(d) under
the Act, filed with the Commission), the sending or giving, by any Underwriter, of any Permitted Free Writing Prospectus will
satisfy the provisions of Rule 164 and Rule 433 (without reliance on subsections (b), (c) and (d) of Rule 164); the Preliminary
Prospectus dated September 28, 2016 is a prospectus that, other than by reason of Rule 433 or Rule 431 under the Act, satisfies
the requirements of Section 10 of the Act, including a price range where required by rule; the conditions set forth in one or
more of subclauses (i) through (iv), inclusive, of Rule 433(b)(1) under the Act are satisfied; neither the Company nor the Underwriters
are disqualified, by reason of subsection (f) or (g) of Rule 164 under the Act, from using, in connection with the offer and sale
of the Shares, &ldquo;free writing prospectuses&rdquo; (as defined in Rule 405 under the Act) pursuant to Rules 164 and 433 under
the Act; the Company is not an &ldquo;ineligible issuer&rdquo; (as defined in Rule 405 under the Act) as of the eligibility determination
date for purposes of Rules 164 and 433 under the Act with respect to the offering of the Shares contemplated by the Registration
Statement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
financial statements of the Company, together with the related notes, set forth or incorporated by reference, in the Registration
Statement, the Disclosure Package and the Prospectus comply in all material respects with the requirements of the Act and fairly
present the financial condition of the Company and its Subsidiaries (defined below) as of the dates indicated and the results
of operations and changes in cash flows for the periods therein specified in conformity with generally accepted accounting principles
in the United States consistently applied throughout the periods involved; and the supporting schedules included in the Registration
Statement, the Disclosure Package and the Prospectus have been derived from the accounting records of the Company and its Subsidiaries
and present fairly the information required to be stated therein. No other schedules or other financial statements are required
to be included in the Registration Statement, the Disclosure Package or the Prospectus. To the Company&rsquo;s knowledge, GBH
CPAs, PC, which has expressed its opinion with respect to the financial statements filed as a part of the Registration Statement
and included in the Registration Statement, the Disclosure Package and the Prospectus, is (x) an independent public accounting
firm within the meaning of the Act, (y) a registered public accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley
Act of 2002 (the &ldquo;<B><I>Sarbanes-Oxley Act</I></B>&rdquo;)) and (z) in the performance of their work for the Company, not
in violation of the auditor independence requirements of the Sarbanes-Oxley Act. Except as described in the Disclosure Package
and the Prospectus, there are no material off-balance sheet transactions, arrangements, obligations (including contingent obligations),
or any other relationships with unconsolidated entities or other persons, that may have a current or, to the knowledge of the
Company, future material adverse effect on the Company&rsquo;s or its Subsidiaries&rsquo; financial condition, changes in financial
condition, results of operations, liquidity, capital expenditures, capital resources or significant components of revenue or expenses;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware.
The Company has full corporate power and authority to own its properties and conduct its business as currently being conducted
and as described in the Registration Statement, the Disclosure Package and the Prospectus, and is duly qualified to do business
as a foreign corporation in good standing in each jurisdiction in which it owns or leases real property or in which the conduct
of its business makes such qualification necessary and in which the failure to so qualify would reasonably be expected to result
in a material adverse change in the business, prospects, management, properties, operations, condition (financial or otherwise)
of the Company and its Subsidiaries, taken as a whole (&ldquo;<B><I>Material Adverse Change</I></B>&rdquo;). The Company has no
subsidiaries (as defined under the Act) other than those listed on Exhibit 21.1 to the Company&rsquo;s Annual Report on Form 10-K
for the year ended December 31, 2015 (collectively, the &ldquo;<B><I>Subsidiaries</I></B>&rdquo;); except as disclosed in the
Registration Statement, the Disclosure Package and the Prospectus, the Company owns, directly or indirectly, all of the issued
and outstanding membership interests or capital stock, as applicable, of each of the Subsidiaries; other than the membership interests
and capital stock of its Subsidiaries, the Company does not own, directly or indirectly, any shares of stock or any other equity
interests or long-term debt securities of any corporation, firm, partnership, joint venture, association or other entity; complete
and correct copies of the charters and the bylaws or similar organizational documents of the Company and the Subsidiaries and
all amendments thereto have been delivered to the Representative, and no changes therein will be made on or after the date hereof
through and including the Time of Purchase and the last Additional Time of Purchase, if any; each Subsidiary has been duly formed
or incorporated, as applicable, and is validly existing as a corporation in good standing under the laws of the jurisdiction of
its incorporation, with full corporate power and authority to own, lease and operate its properties and to conduct its business
as described in the Registration Statement, the Disclosure Package and the Prospectus; each Subsidiary is qualified to do business
as a foreign corporation and is in good standing in each jurisdiction where the ownership or leasing of its properties or the
conduct of its business requires such qualification, except where the failure to be so qualified and in good standing would not,
individually or in the aggregate, result in a Material Adverse Change; all of the outstanding membership interests or shares of
capital stock, as applicable, of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and non-assessable,
have been issued in compliance with all applicable securities laws, were not issued in violation of any preemptive right, resale
right, right of first refusal or similar right and are owned by the Company subject to no security interest, other encumbrance
or adverse claims; and no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights
to convert any obligation into membership interests or shares of capital stock or ownership interests in the Subsidiaries are
outstanding;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
as contemplated in the Disclosure Package and the Prospectus, subsequent to the respective dates as of which information is given
in the Registration Statement, the Disclosure Package and the Prospectus, (a) neither the Company nor any of its Subsidiaries
has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions, or declared
or paid any dividends or made any distribution of any kind with respect to its capital stock; and (b) there has not been (i)&nbsp;any
change in the capital stock (other than a change in the number of outstanding shares of Common Stock due to the issuance of shares
upon the exercise of outstanding options, warrants or equity compensation awards), (ii)&nbsp;any material change in the short
term or long term debt, or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock,
of the Company or any of its Subsidiaries (other than issuances of options and equity compensation awards under the Company&rsquo;s
existing equity incentive plans), or (iii)&nbsp;any Material Adverse Change or any development that would reasonably be expected
to result in a Material Adverse Change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
as set forth in the Disclosure Package and the Prospectus, there is not pending or, to the knowledge of the Company, threatened
or contemplated, any action, suit or proceeding to which the Company or any of its Subsidiaries is a party or of which any property
or assets owned or leased by the Company or any of its Subsidiaries, any employee benefit plan sponsored by the Company or, to
the Company&rsquo;s knowledge, any officer or director of the Company is the subject before or by any court or governmental agency,
authority or body, or any arbitrator, which, individually or in the aggregate, would reasonably be expected to result in any Material
Adverse Change. There are no current or pending legal, governmental or regulatory actions, suits or proceedings that are required
to be described in the Registration Statement, the Disclosure Package and the Prospectus that have not been so described;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
are no statutes, regulations, contracts or documents that are required to be described in the Registration Statement, the Disclosure
Package and the Prospectus or to be filed as exhibits to the Registration Statement by the Act that have not been so described
or filed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement has been duly authorized, executed and delivered by the Company, and constitutes a valid, legal and binding obligation
of the Company, enforceable in accordance with its terms, except as rights to indemnity hereunder may be limited by federal or
state securities laws and except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws
affecting the rights of creditors generally and subject to general principles of equity. The execution, delivery and performance
of this Agreement and the consummation of the transactions herein contemplated will not (A) conflict with or result in a breach
or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any
lien, charge or encumbrance upon any property or assets of the Company or any of its Subsidiaries pursuant to, any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a
party or by which the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company or
any of its Subsidiaries is subject, except as would not reasonably be expected to result in a Material Adverse Change, (B) result
in any violation of the provisions of the charter or by-laws of the Company or any of its Subsidiaries or (C) result in the material
violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory
authority. No consent, approval, authorization or order of, or filing with, any court or governmental agency or body is required
for the execution, delivery and performance of this Agreement or for the consummation of the transactions contemplated hereby,
including the issuance and sale of the Shares by the Company, except such as may be required under the Act, the rules of the Financial
Industry Regulatory Authority (&ldquo;<B><I>FINRA</I></B>&rdquo;), NYSE MKT or state securities or blue sky laws; and the Company
has full corporate power and authority to enter into this Agreement and to consummate the transactions contemplated hereby, including
the authorization, issuance and sale of the Shares as contemplated by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
of the issued and outstanding shares of capital stock of the Company, including the Shares to be sold by the Company and all other
outstanding shares of Common Stock, are duly authorized and validly issued, fully paid and nonassessable, have been issued in
compliance with all federal and state securities laws, were not issued in violation of or subject to any preemptive rights or
other rights to subscribe for or purchase securities that have not been waived in writing; the Additional Shares which may be
sold hereunder by the Company have been duly authorized and, when issued, delivered and paid for in accordance with the terms
of this Agreement, will have been validly issued and will be fully paid and nonassessable; and the capital stock of the Company,
including the Common Stock, conforms to the description thereof in the Registration Statement, the Disclosure Package and the
Prospectus. Except as otherwise described in the Registration Statement, the Disclosure Package and the Prospectus, there are
no preemptive rights or other rights to subscribe for or to purchase, or any restriction upon the voting or transfer of, any shares
of Common Stock pursuant to the Company&rsquo;s charter, by laws or any agreement or other instrument to which the Company is
a party or by which the Company is bound. Except as otherwise described in the Registration Statement, the Disclosure Package
and the Prospectus, neither the filing of the Registration Statement nor the offering or sale of the Shares as contemplated by
this Agreement gives rise to any rights for or relating to the registration of any shares of Common Stock or other securities
of the Company. The Shares to be issued and sold by the Company, after they are delivered against payment therefor as provided
herein, will be, free of preemptive rights, resale rights, rights of first refusal and similar rights and will be free of any
restriction upon the voting or transfer thereof, in each case, pursuant to Delaware Law, the Company&rsquo;s charter or bylaws
or any agreement or other instrument to which the Company is a party. Except as described or contemplated in the Registration
Statement, the Disclosure Package and the Prospectus, there are no options, warrants, agreements, contracts or other rights in
existence to purchase or acquire from the Company any shares of the capital stock of the Company. The Company has an authorized
and outstanding capitalization as set forth in the Registration Statement, the Disclosure Package and the Prospectus. The description
of the Company&rsquo;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted
thereunder, set forth in the Disclosure Package and the Prospectus accurately and fairly presents the information required to
be shown with respect to such plans, arrangements, options and rights;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
as described in the Disclosure Package and the Prospectus, the Company and each Subsidiary possesses all material licenses, certificates,
permits and other authorizations issued by, and has made all declarations and filings with, the appropriate federal, state, local
or foreign governmental or regulatory authorities that are necessary for the ownership or lease of its properties or the conduct
of its business, except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse
Change; except as described in the Disclosure Package and the Prospectus, neither the Company nor any Subsidiary has received
notice of any revocation or modification of any such license, certificate, permit or authorization or has received any notice
that any such license, certificate, permit or authorization will not be renewed in the ordinary course; and the Company and each
Subsidiary is in compliance with all applicable federal, state, local and foreign laws, regulations, orders and decrees except
as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company and each of its Subsidiaries has good and marketable title to all property (whether real or personal) described in the
Registration Statement, the Disclosure Package and the Prospectus as being owned by it, in each case free and clear of all liens,
claims, security interests, other encumbrances or defects, except as described in the Registration Statement, the Disclosure Package
and the Prospectus, and except those that would not, individually or in the aggregate, reasonably be expected to result in a Material
Adverse Change. The property held under lease by the Company or any of its Subsidiaries is held by it under valid, subsisting
and enforceable leases with respect to the Company or its Subsidiaries, as applicable, with only such exceptions with respect
to any particular lease as do not interfere in any material respect with the conduct of the business of the Company or such Subsidiary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company and its Subsidiaries own, possess, license or can acquire or license on reasonable terms all Intellectual
Property necessary for the conduct of the Company&rsquo;s and its Subsidiaries&rsquo; business as now conducted or as
described in the Registration Statement, the Disclosure Package and the Prospectus as being owned or licensed by them, except as
such failure to own, possess, license or acquire such rights would not reasonably be expected to result in a Material Adverse
Change. Except as set forth in the Registration Statement, the Disclosure Package and the Prospectus, (A) to the knowledge of
the Company, there is no infringement, misappropriation or violation by third parties of any such Intellectual Property,
except as such infringement, misappropriation or violation would not reasonably be expected to result in a Material Adverse
Change; (B) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others
challenging the Company&rsquo;s or any of its Subsidiaries&rsquo; rights in or to any such Intellectual Property, and the
Company is unaware of any facts which would form a reasonable basis for any such claim, except for any claim as would not
reasonably be expected to result in a Material Adverse Change; (C) the Intellectual Property owned by the Company and its
Subsidiaries and, to the knowledge of the Company, the Intellectual Property licensed to the Company and its Subsidiaries
have not been adjudged invalid or unenforceable, in whole or in part, in any respect that would be material to the Company,
and there is no pending or threatened action, suit, proceeding or claim by others challenging the validity or scope of any
such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim,
except for any claim as would not reasonably be expected to result in a Material Adverse Change; (D) there is no pending or,
to the knowledge of the Company, threatened action, suit, proceeding or claim by others that the Company or any of its
Subsidiaries infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of
others, neither the Company nor any of its Subsidiaries has received any written notice of such claim, and the Company is
unaware of any facts which would form a reasonable basis for any such claim, except for any claim as would not reasonably be
expected to result in a Material Adverse Change; and (E) to the Company&rsquo;s knowledge, no employee of the Company or any
of its Subsidiaries is in or has ever been in violation of any term of any employment contract, patent disclosure agreement,
invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any
restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s
employment with the Company or any of its Subsidiaries or actions undertaken by the employee while employed with the Company
of any of its Subsidiaries, except for any violation as would not reasonably be expected to result in a Material Adverse
Change. &ldquo;<B><I>Intellectual Property</I></B>&rdquo; shall mean all patents, patent applications, trade and service
marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology,
know-how and other intellectual property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;neither
the Company nor any of its Subsidiaries is (A) in violation of its charter or by laws; (B) in breach of or otherwise in default,
and no event has occurred which, with notice or lapse of time or both, would constitute such a default in the performance or observance
of any term, covenant, obligation, agreement or condition contained in any bond, debenture, note, indenture, loan agreement, mortgage,
deed of trust or any other contract, lease or other instrument to which it is subject or by which it may be bound, or to which
any of the material property or assets of the Company or any of its Subsidiaries is subject; or (C) in violation of any law or
statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except
in the case of (B) and (C) above, as would not, individually or in the aggregate, reasonably be expected to result in a Material
Adverse Change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company and each of its Subsidiaries has timely filed all federal, state, local and foreign income and franchise tax returns required
to be filed (or have timely requested and received applicable extension therefor) and is not in default in the payment of any
material taxes which were payable pursuant to said returns or any assessments with respect thereto, other than any which the Company
or any of its Subsidiaries is contesting in good faith. There is no pending dispute with any taxing authority relating to any
of such returns and the Company has no knowledge of any proposed liability for any tax to be imposed upon the properties or assets
of the Company or any of its Subsidiaries for which there is not an adequate reserve reflected in the Company&rsquo;s financial
statements included in the Registration Statement, the Disclosure Package and the Prospectus;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company has not distributed and will not distribute any prospectus or other offering material in connection with the offering
and sale of the Shares other than the Disclosure Package or the Prospectus or other materials permitted by the Act to be distributed
by the Company; <I>provided, however,</I> that, except as set forth on <U>Schedule B</U>, the Company has not made and will not
make any offer relating to the Shares that would constitute a &ldquo;free writing prospectus&rdquo; as defined in Rule 405 under
the Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Common Stock of the Company is registered and listed on NYSE MKT under the ticker symbol &ldquo;ATNM.&rdquo; The Company has not
received any notice that it is not in compliance with the listing or maintenance requirements of NYSE MKT. The Company believes
that it is, and has no reason to believe that it will not in the foreseeable future continue to be in material compliance with
all such listing and maintenance requirements. To the Company&rsquo;s knowledge, except as described in the Registration Statement,
the Disclosure Package or the Prospectus, there are no affiliations among the Company&rsquo;s directors and officers and members
of FINRA. A Registration Statement relating to the Common Stock on Form 8-A or other applicable form under the Exchange Act has
become effective;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as disclosed in the Registration Statement, in the Disclosure Package and in the Prospectus, the Company maintains a system of
internal accounting controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance with
management&rsquo;s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles in the United States and to maintain accountability for
assets; (C) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (D)
the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. Except as disclosed in the Registration Statement, in the Disclosure Package and in the Prospectus,
the Company&rsquo;s internal control over financial reporting is effective; none of the Company, its board of directors and audit
committee is aware of any &ldquo;significant deficiencies&rdquo; or &ldquo;material weaknesses&rdquo; (each as defined by the
Public Company Accounting Oversight Board) in its internal control over financial reporting, or any fraud, whether or not material,
that involves management or other employees of the Company who have a significant role in the Company&rsquo;s internal controls;
and since the end of the latest audited fiscal year, there has been no change in the Company&rsquo;s internal control over financial
reporting (whether or not remediated) that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s
internal control over financial reporting;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company&rsquo;s board of directors has validly appointed an audit committee whose composition satisfies the applicable requirements
of Rule 803A(2) of the NYSE MKT Company Guide (the &ldquo;<B><I>NYSE MKT Rules</I></B>&rdquo;) and the Company&rsquo;s board of
directors and/or the audit committee has adopted a charter that satisfies the requirements of Rule 803B(1) of the NYSE MKT Rules.
Neither the Company&rsquo;s board of directors nor the audit committee has been informed, nor is any director of the Company aware,
of (A) any &ldquo;significant deficiencies&rdquo; or &ldquo;material weaknesses&rdquo; (other than as disclosed in the Registration
Statement, the Disclosure Package and the Prospectus) in the design or operation of the Company&rsquo;s internal controls which
could adversely affect the Company&rsquo;s ability to record, process, summarize and report financial data or any material weakness
in the Company&rsquo;s internal controls; or (B) any fraud, whether or not material, that involves management or other employees
of the Company who have a significant role in the Company&rsquo;s internal control over financial reporting;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no
relationship, direct or indirect, exists between or among the Company and its Subsidiaries, on the one hand, and the directors,
officers, stockholders, customers or suppliers of the Company and its Subsidiaries, on the other hand, which is required to be
described in the Registration Statement, the Disclosure Package and the Prospectus which is not so described. Neither the Company
nor any of its Subsidiaries has, directly or indirectly, extended or maintained credit, or arranged for the extension of credit,
or renewed an extension of credit, in the form of a personal loan to or for any of its directors or executive officers in violation
of applicable laws, including Section 402 of the Sarbanes-Oxley Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company and each of its Subsidiaries:
(A) is and at all times has been in compliance with all statutes, rules, regulations, or guidance applicable to Company or any
of its Subsidiaries and the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing,
labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the
Company or any of its Subsidiaries (&ldquo;<B><I>Applicable Laws</I></B>&rdquo;), except as would not, individually or in the
aggregate, reasonably be expected to result in a Material Adverse Change; (B) has not received any FDA Form 483 notice of adverse
finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration or any federal,
state, local or foreign governmental authority having authority over the Company or any of its Subsidiaries (&ldquo;<B><I>Governmental
Authority</I></B>&rdquo;) alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals,
clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<B><I>Authorizations</I></B>&rdquo;);
(C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and is not in violation
of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any Governmental Authority or third party alleging that any product operation
or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Authority
or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not
received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke
any Authorizations and has no knowledge that any such Governmental Authority is considering such action; and (F) has filed, obtained,
maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments were complete and correct in all material respects on the date filed
(or were corrected or supplemented by a subsequent submission);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the preclinical tests and clinical trials, and other studies (collectively, &ldquo;studies&rdquo;) that are described in, or the
results of which are referred to in, the Registration Statement, the Disclosure Package or the Prospectus were and, if still pending,
are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for
such studies and with standard medical and scientific research procedures; each description of the results of such studies is
accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company has no
knowledge of any other studies the results of which are materially inconsistent with, or otherwise reasonably call into question
in any material respect, the results described or referred to in the Registration Statement, the Disclosure Package or the Prospectus;
the Company has made all such filings and obtained all such approvals and authorizations as may be required by the Food and Drug
Administration of the U.S. Department of Health and Human Services or from any other U.S. or foreign government or drug or medical
device regulatory agency (collectively, the &ldquo;Regulatory Agencies&rdquo;), or health care facility Institutional Review Board
or Ethics Review Board (collectively, the &ldquo;Review Boards&rdquo;), except where the failure to make such filing or obtain
such approval or authorization could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse
Change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except as disclosed in the Registration Statement, Disclosure Package or the Prospectus, neither the Company nor any
of its Subsidiaries has received any written notices or statements from the Regulatory Agencies, the Review Boards or any other
governmental agency, and otherwise has no knowledge or reason to believe, that (i) any new drug application or marketing authorization
application for any product or potential product of the Company or any of its Subsidiaries is or has been rejected or determined
to be non-approvable or conditionally approvable; (ii) a delay in time for review and/or approval of a marketing authorization
application or marketing approval application in any other jurisdiction for any product or potential product of the Company or
any of its Subsidiaries is or may be required, requested or being implemented; (iii) one or more clinical studies for any product
or potential product of the Company or any of its Subsidiaries shall or may be requested or required in addition to the clinical
studies described in the Registration Statement, the Disclosure Package or the Prospectus as a precondition to or condition of
issuance or maintenance of a marketing approval for such product or potential product; (iv) any license, approval, permit or authorization
to conduct any clinical trial of or market any product or potential product of the Company or any of its Subsidiaries has been,
will be or may be suspended, revoked, modified or limited, except in the cases of clauses (i), (ii), (iii) and (iv) where such
rejections, determinations, delays, requests, suspensions, revocations, modifications or limitations would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except as disclosed in the Registration Statement, the
Disclosure Package and the Prospectus, to the Company&rsquo;s knowledge, the preclinical and clinical testing, application for
marketing approval of, manufacture, distribution, promotion and sale of the products and potential products of the Company or
any of its Subsidiaries is in compliance, in all material respects, with all laws, rules and regulations applicable to such activities,
including without limitation applicable good laboratory practices, good clinical practices and good manufacturing practices, except
for such non-compliance as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change.
The descriptions of the results of such tests and trials contained in the Registration Statement, the Disclosure Package and the
Prospectus are accurate in all material respects. Except to the extent disclosed in the Registration Statement, the Disclosure
Package and the Prospectus, neither the Company nor any of its Subsidiaries has received notice of adverse finding, warning letter
or clinical hold notice from the FDA or any non-U.S. counterpart of any of the foregoing, or any untitled letter or other correspondence
or notice from the FDA or any other governmental authority or agency or any institutional or ethical review board alleging or
asserting noncompliance with any law, rule or regulation applicable in any jurisdiction, except notices, letters, and correspondences
and non-U.S. counterparts thereof alleging or asserting such noncompliance as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Change. Except as disclosed in the Registration Statement, the Disclosure Package and the
Prospectus, neither the Company nor any of its Subsidiaries has, either voluntarily or involuntarily, initiated, conducted or
issued, or caused to be initiated, conducted or issued, any recall, field correction, market withdrawal or replacement, safety
alert, warning, &ldquo;dear doctor&rdquo; letter, investigator notice, or other notice or action relating to an alleged or potential
lack of safety or efficacy of any product or potential product of the Company or any of its Subsidiaries, any alleged product
defect of any product or potential product of the Company or any of its Subsidiaries, or any violation of any material applicable
law, rule, regulation or any clinical trial or marketing license, approval, permit or authorization for any product or potential
product of the Company or any of its Subsidiaries, and the Company is not aware of any facts or information that would cause it
to initiate any such notice or action and has no knowledge or reason to believe that the Regulatory Agencies, the Review Boards
or any other governmental agency or authority or any institutional or ethical review board or other non-governmental authority
intends to impose, require, request or suggest such notice or action. The pre-clinical or clinical studies, tests, investigations,
and trials conducted by or on behalf of the Company or any of its Subsidiaries are described in the Registration Statement, the
Disclosure Package and the Prospectus were and, if still in progress, are being, conducted in compliance with all applicable U.S.
and foreign statutes, rules, regulations, orders, or other laws, and, for any data to be submitted to the FDA pursuant to such
studies, all applicable good laboratory practices and good clinical practices in all material respects. The descriptions of the
pre-clinical or clinical studies, tests, investigations, and trials, including the related results and regulatory status thereof,
contained in the Registration Statement, the Disclosure Package and the Prospectus are accurate in all material respects. Neither
the Company nor any of its Subsidiaries has received and is otherwise not aware of any notices, correspondence or other communication
from the FDA or other governmental regulatory agency or subdivision thereof, or any institutional or ethical review boards, asserting
non-compliance with any applicable statutes, rules, regulations, orders, or other laws, or requiring or requesting the termination,
suspension or modification of any preclinical or clinical studies, tests, investigations, or trials conducted by, or on behalf
of, the Company or any of its Subsidiaries or in which the Company or any of its Subsidiaries has participated;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company and each of its Subsidiaries (A) is in compliance with any and all applicable federal, state, local and foreign laws,
rules, regulations, decisions and orders relating to the protection of human health and safety, the environment or hazardous or
toxic substances or wastes, pollutants or contaminants (collectively, &ldquo;<B><I>Environmental Laws</I></B>&rdquo;); (B) has
received and is in compliance with all permits, licenses or other approvals required of it under applicable Environmental Laws
to conduct its business; and (C) has not received notice of any actual or potential liability for the investigation or remediation
of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except in any such case for
any such failure to comply, or any such failure to receive required permits, licenses or approvals, or any such liability as would
not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company and each of its Subsidiaries (A) is in compliance, in all material respects, with any and all applicable foreign,
federal, state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all governmental
authorities (including pursuant to the Occupational Health and Safety Act) relating to the protection of human health and
safety in the workplace (&ldquo;<B><I>Occupational Laws</I></B>&rdquo;); (B) has received all material permits, licenses or
other approvals required of it under applicable Occupational Laws to conduct its business as currently conducted; and (C) is
in compliance, in all material respects, with all terms and conditions of such permit, license or approval. No action,
proceeding, revocation proceeding, writ, injunction or claim is pending or, to the Company&rsquo;s knowledge, threatened
against the Company or any of its Subsidiaries relating to Occupational Laws, and the Company does not have knowledge of any
facts, circumstances or developments relating to its operations that would reasonably be expected to form the basis for or
give rise to such actions, suits, investigations or proceedings;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (&ldquo;<B><I>ERISA</I></B>&rdquo;),
that is maintained, administered or contributed to by the Company or any of its Subsidiaries for employees or former employees
of the Company and its Subsidiaries or to which the Company or its Subsidiaries has any direct or indirect liability, whether
contingent or otherwise (each, a &ldquo;<B><I>Company Plan</I></B>&rdquo;), has been maintained in material compliance with its
terms and the requirements of any applicable statutes, orders, rules and regulations, including, but not limited to, ERISA and
the Internal Revenue Code of 1986, as amended (the &ldquo;<B><I>Code</I></B>&rdquo;). No prohibited transaction, within the meaning
of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Company Plan excluding transactions effected
pursuant to a statutory or administrative exemption; and for each Company Plan that is subject to the funding rules of Section
412 of the Code or Section 302 of ERISA, no &ldquo;accumulated funding deficiency&rdquo; as defined in Section 412 of the Code
has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes
accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable
actuarial assumptions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)&nbsp;&nbsp;&nbsp;&nbsp;except
as set forth in the Registration Statement, the Disclosure Package and the Prospectus, neither the Company nor any of its Subsidiaries
has granted rights to develop, manufacture, produce, assemble, distribute, license, market or sell its products to any other person
that are material to the Company nor is it bound by any agreement that affects the Company&rsquo;s or any Subsidiary&rsquo;s exclusive
right to develop, manufacture, produce, assemble, distribute, license, market or sell its products that are material to the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;nothing
has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included
in the Registration Statement, the Disclosure Package and the Prospectus is not based on or derived from sources that are reliable
and accurate in all material respects and the Company has obtained the written consent to the use of such data from such sources to the extent required;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)&nbsp;&nbsp;&nbsp;&nbsp;other
than as contemplated by this Agreement, there is no broker, finder or other party that is entitled to receive from the Company
or any of its Subsidiaries any broker&rsquo;s or finder&rsquo;s fee or agent&rsquo;s commission or other fee or commission in
connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby, except
as previously waived;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company and each of its Subsidiaries carries, or is covered by, insurance issued by insurers of nationally recognized financial
responsibility in such amounts and covering such risks as is adequate for the conduct of its business and the value of its properties
and as is customary for companies engaged in similar businesses in similar industries; and neither the Company nor any of its
Subsidiaries has (A) received notice from any insurer or agent of such insurer that capital improvements or other expenditures
are required or necessary to be made in order to continue such insurance or (B) reason to believe that it will not be able to
renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from
similar insurers as may be necessary to continue its business. All such insurance is outstanding and duly in force on the date
hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;neither
the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or other
person associated with or acting on behalf of the Company or any of its Subsidiaries has (A) used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (B) made any direct or indirect
unlawful payment to any foreign or domestic government official or employee from corporate funds; (C) violated or is in violation
of any provision of the Foreign Corrupt Practices Act of 1977; or (D) made any bribe, rebate, payoff, influence payment, kickback
or other unlawful payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)&nbsp;&nbsp;&nbsp;&nbsp;neither
the Company nor any of its Subsidiaries is and, after giving effect to the offering and sale of the Shares, will be an &ldquo;investment
company,&rdquo; as such term is defined in the Investment Company Act of 1940, as amended;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)&nbsp;&nbsp;&nbsp;&nbsp;the
conditions for use of Form S-3 set forth in the General Instructions thereto have been satisfied;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Company and its Subsidiaries are in material compliance with all applicable provisions of the Sarbanes-Oxley Act and the
rules and regulations of the Commission thereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
as set forth in the Registration Statement, the Disclosure Package and the Prospectus, the Company and its Subsidiaries have established
and maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and such
controls and procedures are effective in ensuring that material information relating to the Company and its Subsidiaries is made
known to the principal executive officer and the principal financial officer. The Company and its Subsidiaries have utilized such
controls and procedures in preparing and evaluating the disclosures in the Registration Statement, in the Disclosure Package and
in the Prospectus;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company has obtained for the benefit of the Underwriters the agreement, in the form satisfactory to the Underwriters, of each
of its directors and &ldquo;officers&rdquo; (within the meaning of Rule 16a-1(f) under the Exchange Act) (each, a &ldquo;<B><I>Lock-Up
Agreement</I></B>&rdquo; and collectively, the &ldquo;<B><I>Lock-Up Agreements</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;neither the Company nor any of its Subsidiaries is and, after giving effect to the offering and sale of the Shares, will be
a &ldquo;holding company&rdquo; or a &ldquo;subsidiary company&rdquo; of a &ldquo;holding company&rdquo; or an &ldquo;affiliate&rdquo;
of a &ldquo;holding company&rdquo; or of a &ldquo;subsidiary company,&rdquo; as such terms are defined in the Public Utility
Holding Company Act of 1935, as amended;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)&nbsp;&nbsp;&nbsp;neither
the Company nor any of its Subsidiaries are engaged in any unfair labor practice; except for matters which would not, individually
or in the aggregate, reasonably be expected to result in a Material Adverse Change, (i) there is (A) no unfair labor practice
complaint pending or, to the Company&rsquo;s knowledge, threatened against the Company or any of its Subsidiaries before the National
Labor Relations Board, and no grievance or arbitration proceeding arising out of or under collective bargaining agreements is
pending or, to the Company&rsquo;s knowledge, threatened, (B) no strike, labor dispute, slowdown or stoppage pending or, to the
Company&rsquo;s knowledge, threatened against the Company or any of its Subsidiaries and (C) no union representation dispute currently
existing concerning the employees of the Company or any of its Subsidiaries, (ii) to the Company&rsquo;s knowledge, no union organizing
activities are currently taking place concerning the employees of the Company or any of its Subsidiaries and (iii) there has been
no violation of any federal, state, local or foreign law relating to discrimination in the hiring, promotion or pay of employees,
any applicable wage or hour laws, any provision of the Worker Adjustment and Retraining Notification Act of 1988, as amended (&ldquo;<B><I>WARN
Act</I></B>&rdquo;), or the WARN Act&rsquo;s state, foreign or local equivalent, or any provision of the Employee Retirement Income
Security Act of 1974 or the rules and regulations promulgated thereunder concerning the employees of the Company or any of its
Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)&nbsp;&nbsp;&nbsp;&nbsp;each &ldquo;forward-looking statement&rdquo; (within the meaning of Section 27A of the Act or Section 21E of the Exchange
Act) contained or incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus has been
made or reaffirmed with a reasonable basis and in good faith;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)&nbsp;&nbsp;&nbsp;&nbsp;the
operations of its Company and the Subsidiaries are and have been conducted at all times in material compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;<B><I>Money Laundering Laws</I></B>&rdquo;);
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator or non-governmental
authority involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the Company&rsquo;s
knowledge, threatened;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)&nbsp;&nbsp;&nbsp;&nbsp;neither
the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate
of the Company or any of its Subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;<B><I>OFAC</I></B>&rdquo;); and the Company will not directly or indirectly use
the proceeds of the offering of the Shares contemplated hereby, or lend, contribute or otherwise make available such proceeds
to any of its Subsidiaries, joint venture partner or other person or entity, for the purpose of financing the activities of any
person known by the Company currently subject to any U.S. sanctions administered by OFAC;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)&nbsp;&nbsp;&nbsp;&nbsp;no
Subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to the Company,
from making any other distribution on such Subsidiary&rsquo;s capital stock, from repaying to the Company any loans or
advances to such Subsidiary from the Company or from transferring any of such Subsidiary&rsquo;s property or assets to the
Company or any other Subsidiary of the Company, except as described in the Registration Statement (excluding the exhibits
thereto), the Disclosure Package and the Prospectus;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company has not received any notice from NYSE MKT regarding the delisting of the Common Stock from NYSE MKT;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;neither
the Company nor any of its Subsidiaries nor any of their respective directors, officers or, to the knowledge of the Company, any
of their affiliates or controlling persons has taken, directly or indirectly, any action designed, or which has constituted or
might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of the Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(tt)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the issuance and sale of the Shares to be sold by the Company as contemplated hereby will not cause any holder of any
shares of capital stock, securities convertible into or exchangeable or exercisable for capital stock or options, warrants
or other rights to purchase capital stock or any other securities of the Company to have any right to acquire any shares of
capital stock of the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In addition, any certificate signed by any officer of the Company or any of its Subsidiaries
and delivered to the Underwriters or counsel for the Underwriters in connection with the offering of the Shares shall be deemed
to be a representation and warranty by the Company, as to matters covered thereby, to each Underwriter.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Covenants of the Company</U>. The Company hereby agrees:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
furnish such information as may be required and otherwise to cooperate in qualifying the Shares for offering and sale under the
securities or blue sky laws of such states or other jurisdictions as the Underwriters may designate and to maintain such qualifications
in effect so long as the Underwriters may request for the distribution of the Shares; provided, however, that the Company shall
not be required to qualify as a foreign corporation or to consent to the service of process under the laws of any such jurisdiction
(except service of process with respect to the offering and sale of the Shares); and to promptly advise the Underwriters of the
receipt by the Company of any notification with respect to the suspension of the qualification of the Shares for offer or sale
in any jurisdiction or the initiation or threatening of any proceeding for such purpose;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
make available to the Underwriters, as soon as practicable after this Agreement becomes effective, and thereafter from time to
time to furnish to the Underwriters, as many copies of each Permitted Free Writing Prospectus, any Preliminary Prospectus and
the Prospectus (or of the Prospectus as amended or supplemented if the Company shall have made any amendments or supplements thereto
after the Effective Time) as the Representative may reasonably request for the purposes contemplated by the Act; to prepare the
Prospectus in a form approved by the Underwriters and to file such Prospectus pursuant to Rule 424(b) under the Act not later
than Commission&rsquo;s close of business on the second business day following the execution and delivery of this Agreement, or,
if applicable, such earlier time as may be required by the rules and regulations of the Commission under the Act; and in case
any Underwriter is required to deliver (whether physically or through compliance with Rule 172 under the Act or any similar rule),
in connection with the sale of the Shares, a prospectus after the nine-month period referred to in Section 10(a)(3) of the Act,
or after the time a post-effective amendment to the Registration Statement is required pursuant to Item 512(a) of Regulation S-K
under the Act, the Company will prepare, at its expense, promptly upon request such amendment or amendments to the Registration
Statement and the Prospectus as may be necessary to permit compliance with the requirements of Section 10(a)(3) of the Act or
Item 512(a) of Regulation S-K under the Act, as the case may be;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
give the Representative notice of its intention to file or prepare any amendment to the Registration Statement (including any
filing under Rule 462(b)) or any amendment, supplement or revision to the prospectus included in the Registration Statement at
the time it became effective, any other preliminary prospectus, the Prospectus or any Permitted Free Writing Prospectus, whether
pursuant to the Act or otherwise, and will furnish the Representative with copies of any such documents within a reasonable amount
of time prior to such proposed filing or use, as the case may be, and will not file or use any such document to which the Representative
or counsel for the Underwriters shall object;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if,
at any time during the period when a prospectus is required by the Act to be delivered (whether physically or through compliance
with Rule 172 under the Act or any similar rule) in connection with any sale of Shares, the Registration Statement shall cease
to comply with the requirements of the Act with respect to eligibility for the use of the form on which the Registration Statement
was filed with the Commission, to (i) promptly notify the Representative, (ii) promptly file with the Commission a new registration
statement under the Act, relating to the Shares, or a post-effective amendment to the Registration Statement, which new registration
statement or post-effective amendment shall comply with the requirements of the Act and shall be in a form satisfactory to the
Representative, (iii) use its best efforts to cause such new registration statement or post-effective amendment to become effective
under the Act as soon as practicable, (iv) promptly notify the Representative of such effectiveness and (v) take all other action
necessary or appropriate to permit the public offering and sale of the Shares to continue as contemplated in the Prospectus; all
references herein to the Registration Statement shall be deemed to include each such new registration statement or post-effective
amendment, if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
advise the Representative promptly, confirming such advice in writing, of any request by the Commission for amendments or supplements
to the Registration Statement, any Preliminary Prospectus, the Prospectus or any Permitted Free Writing Prospectus or for additional
information with respect thereto, or of notice of institution of proceedings for, or the entry of a stop order, suspending the
effectiveness of the Registration Statement and, if the Commission should enter a stop order suspending the effectiveness of the
Registration Statement, to use its reasonable best efforts to obtain the lifting or removal of such order as soon as possible;
to advise the Representative promptly of any proposal to amend or supplement the Registration Statement, any Preliminary Prospectus
or the Prospectus, and to provide the Underwriters and Underwriters&rsquo; counsel copies of any such documents for review and
comment a reasonable amount of time prior to any proposed filing and to file no such amendment or supplement to which the Representative
shall object in writing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to Section 4(e) hereof, to file promptly all reports and documents and any preliminary or definitive proxy or information statement
required to be filed by the Company with the Commission in order to comply with the Exchange Act for so long as a prospectus is
required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule)
in connection with any sale of Shares; and to provide the Underwriters, for the Underwriters&rsquo; review and comment, with a
copy of such reports and statements and other documents to be filed by the Company pursuant to Section 13, 14 or 15(d) of the
Exchange Act during such period a reasonable amount of time prior to any proposed filing, and to file no such report, statement
or document to which the Representative shall have objected in writing; and to promptly notify the Underwriters of such filing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
advise the Representative promptly of the happening of any event within the period during which a prospectus is required by the
Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in connection with
any sale of Shares, which event could require the making of any change in the Prospectus then being used so that the Prospectus
would not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they are made, not misleading, and to advise the Representative promptly
if, during such period, it shall become necessary to amend or supplement the Prospectus to cause the Prospectus to comply with
the requirements of the Act, and, in each case, during such time, subject to Section 4(e) hereof, to prepare and furnish, at the
Company&rsquo;s expense, to the Underwriters promptly such amendments or supplements to such Prospectus as may be necessary to
reflect any such change or to effect such compliance;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
make generally available to its security holders, and to deliver to the Underwriters, as soon as practicable but in no event later
than 15 months after the end of the Company&rsquo;s current fiscal quarter, an earnings statement of the Company if necessary
to satisfy the provisions of Section 11(a) of the Act covering a period of twelve months which will satisfy the provisions of
Section 11(a) of the Act and Rule 158 under the Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
furnish to the Underwriters two copies of the Registration Statement, as initially filed with the Commission, and of all amendments
thereto (including all exhibits thereto and documents incorporated by reference therein);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
pay all costs, expenses, fees and taxes in connection with (i) the preparation and filing of the Registration Statement, the Basic
Prospectus, each Preliminary Prospectus, the Prospectus Supplement, the Prospectus, each Permitted Free Writing Prospectus and
any amendments or supplements thereto, and the printing and furnishing of copies of each thereof to the Underwriters and to dealers
(including costs of mailing and shipment), (ii) the registration, issuance, sale and delivery of the Shares, including any stock
or transfer taxes and stamp or similar duties payable upon the issuance, sale or delivery of the Shares to the Underwriters, (iii)
the producing, word processing and/or printing of this Agreement, any dealer agreements, any powers of attorney, and any closing
documents (including compilations thereof) and the reproduction and/or printing and furnishing of copies of each thereof to the
Underwriters and (except closing documents) to dealers (including costs of mailing and shipment), (iv) the qualification of the
Shares for offering and sale under state or foreign laws and the determination of their eligibility for investment under state
or foreign laws (including the legal fees and filing fees and other disbursements of counsel for the Underwriters) and the printing
and furnishing of copies of any blue sky surveys or legal investment surveys to the Underwriters and to dealers, (v) any listing
of the Shares on any securities exchange or qualification of the Shares for quotation on NYSE MKT and any registration thereof
under the Exchange Act, (vi) any filing for review of the public offering of the Shares by FINRA (including the legal fees and
filing fees and other disbursements of counsel to the Underwriters relating to FINRA matters), (vii) the fees and disbursements
of any transfer agent or registrar for the Shares, (viii) the costs and expenses of the Company relating to presentations or meetings
undertaken in connection with the marketing of the offering and sale of the Shares to prospective investors and the Underwriters&rsquo;
sales forces, including, without limitation, expenses associated with the production of road show slides and graphics, fees and
expenses of any consultants engaged in connection with the road show presentations, and travel, lodging and other expenses incurred
by the officers of the Company and any such consultants, (ix) the performance of the Company&rsquo;s other obligations hereunder,
and (x) all other costs and expenses of the Underwriters incident to the performance of their obligations hereunder not otherwise
specifically provided for herein and the fees and expenses of the Underwriters&rsquo; legal counsel; provided, however, such costs
and expenses provided for in this subsection (x) and subsections (iv) and (vi) above shall not exceed $85,000 (including fees
of counsel) (collectively, the &ldquo;<B><I>Fee Cap</I></B>&rdquo;); if this Agreement is terminated by the Representative pursuant
to Section 6 hereof or if the sale of the Shares provided for herein is not consummated by reason of any failure, refusal or inability
on the part of the Company to perform any agreement on its part to be performed, or because any other condition of the Underwriters&rsquo;
obligations hereunder required to be fulfilled by the Company is not fulfilled, the Company will reimburse the non-defaulting
Underwriters for all documented reasonable out-of-pocket disbursements (including but not limited to reasonable fees and disbursements
of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges) incurred by the Underwriters in connection
with their investigation, preparing to market and marketing the Shares or in contemplation of performing their obligations hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
comply with Rule 433(d) under the Act (without reliance on Rule 164(b) under the Act) and with Rule 433(g) under the Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.78in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;beginning
on the date hereof and ending on, and including, the date that is 90 days after the date of the Prospectus Supplement (the
&ldquo;<B><I>Lock-Up Period</I></B>&rdquo;), without the prior written consent of Representative (which consent may be
withheld in its sole discretion), not to directly or indirectly, offer for sale, sell, contract to sell, pledge, grant any
option for the sale of, or otherwise issue or dispose of, directly or indirectly (or publicly disclose the intention to make
any such offer, sale, pledge, grant, issuance or other disposition), any Common Stock or any securities convertible into or
exchangeable for, or any options or rights to purchase or acquire, Common Stock, except (A) to the Underwriters pursuant to
this Agreement, (B) to directors, employees or consultants of the Company pursuant any employee stock incentive plan, stock
ownership plan or dividend reinvestment plan of the Company in effect on the date hereof, (C) upon exercise, vesting or
conversion of securities outstanding as of the date hereof and (D) sales of Common Stock pursuant to the At-the-Market
Issuance Sales Agreement between the Company and FBR &amp; Co., LLC (the &ldquo;<B><I>ATM Agreement</I></B>&rdquo;)
commencing on the 31<SUP>st</SUP> day following the earlier of (i) the closing of the sale of all of the Additional Shares
and (ii) the end of the Over-Allotment Period. The Company agrees not to accelerate the vesting of any option or warrant or
the lapse of any repurchase right prior to the expiration of the Lock-Up Period except for acceleration pursuant to change of
control agreements in existence as of the date of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.78in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prior
to the Time of Purchase, to issue no press release or other communication directly or indirectly and hold no press conferences
with respect to the Company or any of its Subsidiaries, the financial condition, results of operations, business, properties,
assets, or liabilities of the Company or any of its Subsidiaries, or the offering of the Shares, without the prior consent of
the Representative (which consent may be withheld in their sole discretion), except as required by law or the listing requirements
of NYSE MKT;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not,
at any time at or after the execution of this Agreement, to, directly or indirectly, offer or sell any Shares by means of any
&ldquo;prospectus&rdquo; (within the meaning of the Act), or use any &ldquo;prospectus&rdquo; (within the meaning of the Act)
in connection with the offer or sale of the Shares, in each case other than the Prospectus;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not
to, and to cause its Subsidiaries not to, take, directly or indirectly, any action designed, or which will constitute, or has
constituted, or would reasonably be expected to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of the Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
use its best efforts to cause the Shares to be listed on NYSE MKT and to maintain the listing of the Common Stock for quotation
on NYSE MKT;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
maintain a transfer agent and, if necessary under the jurisdiction of incorporation of the Company, a registrar for the Common
Stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
use the net proceeds received by it from the issuance and sale of the Shares pursuant to this Agreement in the manner specified
in the Disclosure Package and the Prospectus Supplement under the caption &ldquo;Use of Proceeds&rdquo;; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that,
without the prior consent of the Representative (which consent may be withheld in its sole discretion), it has not made and will
not make any offer relating to the Shares that would constitute a &ldquo;free writing prospectus&rdquo; (as defined in Rule 405
under the Act); the Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Permitted
Free Writing Prospectus, including timely filing with the Commission or retention where required and legending; and the Company
agrees that if at any time following issuance of any Permitted Free Writing Prospectus any event occurred or occurs as a result
of which such Permitted Free Writing Prospectus would conflict with the information in the Registration Statement, the Disclosure
Package or the Prospectus or would include an untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in the light of the circumstances under which they are made, not misleading, the Company
will give prompt notice thereof to the Underwriters and, if requested by the Representative, will prepare and furnish without
charge to the Underwriters a Permitted Free Writing Prospectus or other document which will correct such conflict, statement or
omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
of the Underwriters&rsquo; Obligations</U>. The several obligations of the Underwriters hereunder are subject to the accuracy
of the representations and warranties on the part of the Company on the date hereof and at the Time of Purchase and each Additional
Time of Purchase, if any, the performance by the Company of its obligations hereunder and to the following additional conditions
precedent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.78in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall furnish to the Underwriters at the Time of Purchase and each Additional Time of Purchase, if any, an opinion and
negative assurance statement of The Matt Law Firm, PLLC, counsel for the Company, addressed to the Underwriters, and dated the
Time of Purchase or the Additional Time of Purchase, as the case may be, in form and substance satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.78in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.78in; text-align: justify">(b)<FONT STYLE="font-family: Times New Roman; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company shall furnish to the Underwriters at the Time of Purchase and each Additional Time of Purchase, if any, an opinion of
Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Company, addressed to the Underwriters, and dated the Time of
Purchase or the Additional Time of Purchase, as the case may be, in form and substance satisfactory to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Underwriters shall have received from GBH CPAs, PC letters dated, respectively, the date of this Agreement and the Time of Purchase
and each Additional Time of Purchase, if any, and addressed to the Underwriters in the forms satisfactory to the Underwriters,
which letters shall cover the various financial disclosures contained in the Registration Statement, the Disclosure Package and
the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Underwriters shall have received at the Time of Purchase and each Additional Time of Purchase, if any, the negative assurance
statement of Lowenstein Sandler LLP, counsel for the Underwriters, dated the Time of Purchase or the Additional Time of Purchase,
as the case may be, in form and substance reasonably satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Prospectus or amendment or supplement to the Registration Statement or the Prospectus shall have been filed to which the Representative
shall have objected in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Registration Statement shall be effective under the Act and any registration statement required to be filed, prior to the sale
of the Shares, under the Act pursuant to Rule 462(b) shall have been filed and shall have become effective under the Act. The
Prospectus Supplement shall have been filed with the Commission pursuant to Rule 424(b) under the Act at or before 5:30 P.M.,
New York time, on the second full business day after the date of this Agreement (or such earlier time as may be required under
the Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to and at the Time of Purchase and each Additional Time of Purchase, if any, (i) no stop order with respect to the effectiveness
of the Registration Statement shall have been issued under the Act or proceedings initiated under Section 8(d) or 8(e) of the
Act; (ii) the Registration Statement and all amendments thereto shall not contain an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (iii) none
of the Preliminary Prospectuses or the Prospectus nor any amendment or supplement thereto, shall include an untrue statement of
a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they are made, not misleading; (iv) neither the Disclosure Package, nor any amendment or supplement thereto, shall
include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they are made, not misleading; and (v) none of the Permitted Free Writing Prospectuses,
if any, shall include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they are made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will, at the Time of Purchase and each Additional Time of Purchase, if any, deliver to the Underwriters a certificate
of its Chief Executive Officer and its Principal Financial Officer, dated the Time of Purchase, in a form satisfactory to the
Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Underwriters shall have received each of the signed Lock-Up Agreements referred to in Section 3(ll) hereof, and each such Lock-Up
Agreement shall be in full force and effect at the Time of Purchase and each Additional Time of Purchase, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall have furnished to the Underwriters such other documents and certificates as to the accuracy and completeness of
any statement in the Registration Statement, the Disclosure Package, the Prospectus or any Permitted Free Writing Prospectus as
of the Time of Purchase and each Additional Time of Purchase, if any, as the Representative may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Shares shall have been approved for listing on NYSE MKT, subject only to notice of issuance at or prior to the Time of Purchase
or the Additional Time of Purchase, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FINRA
shall not have raised any objection with respect to the fairness or reasonableness of the underwriting, or other arrangements
of the transactions, contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date of Agreement; Termination</U>. This Agreement shall become effective when the parties hereto have executed and delivered
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the purchase of the Firm Shares by the Underwriters on the Closing Date, the obligations of the several Underwriters hereunder
shall be subject to termination in the absolute discretion of the Representative, if (1) since the time of execution of this Agreement
or the earlier respective dates as of which information is given in the Registration Statement, the Disclosure Package or the
Prospectus, there has been any change or any development involving a prospective change in the business, prospects, management,
properties, operations, condition (financial or otherwise) or results of operations of the Company and its Subsidiaries, or such
change in general market conditions, taken as a whole, the effect of which change or development is, in the judgment of the Representative,
so material and adverse as to make it impractical or inadvisable to proceed with the public offering or the delivery of the Shares
on the terms and in the manner contemplated in the Registration Statement, the Disclosure Package and the Prospectus, or (2) since
the time of execution of this Agreement, there shall have occurred: (A)&nbsp;a suspension or material limitation in trading in
securities generally on NYSE MKT, the New York Stock Exchange or The Nasdaq Stock Market; (B) a suspension or material limitation
in trading in the Company&rsquo;s securities on NYSE MKT; (C) a general moratorium on commercial banking activities declared by
either federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance
services in the United States; (D) an outbreak or escalation of hostilities or acts of terrorism involving the United States or
a declaration by the United States of a national emergency or war; or (E) any other calamity or crisis or any change in financial,
political or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (D) or
(E), in the judgment of the Representative, makes it impractical or inadvisable to proceed with the public offering or the delivery
of the Shares on the terms and in the manner contemplated in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Representative elect to terminate this Agreement as provided in this Section 6, the Company and each other Underwriter
shall be notified promptly in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the sale to the Underwriters of the Shares, as contemplated by this Agreement, is not carried out by the Underwriters for any
reason permitted under this Agreement, or if such sale is not carried out because the Company shall be unable to comply with any
of the terms of this Agreement, the Company shall not be under any obligation or liability under this Agreement (except to the
extent provided in Sections 4(j) and 7 hereof), and the Underwriters shall be under no obligation or liability to the Company
under this Agreement or to one another hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity
and Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to indemnify, defend and hold harmless each Underwriter, its partners, directors and officers, any person
who controls any Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and the successors
and assigns of all of the foregoing persons, from and against any loss, damage, expense, liability or claim (including the
reasonable cost of investigation) which, jointly or severally, any such Underwriter or any such person may incur under the
Act, the Exchange Act, the common law or otherwise, insofar as such loss, damage, expense, liability or claim arises out of
or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement
(or in the Registration Statement as amended by any post-effective amendment thereof by the Company) or arises out of or is
based upon any omission or alleged omission to state a material fact required to be stated therein or necessary to make the
statements therein not misleading, except insofar as any such loss, damage, expense, liability or claim arises out of or is
based upon any untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information
concerning such Underwriter furnished in writing by or on behalf of such Underwriter through the Representative to the Company
expressly for use in, the Registration Statement or arises out of or is based upon any omission or alleged omission to state
a material fact in the Registration Statement in connection with such information, which material fact was not contained in
such information and which material fact was required to be stated in such Registration Statement or was necessary to make
such information not misleading or (ii) any untrue statement or alleged untrue statement of a material fact included in any
Prospectus (the term Prospectus for the purpose of this Section 7 being deemed to include the Basic Prospectus, each Preliminary
Prospectus, the Prospectus Supplement, the Prospectus and any amendments or supplements to the foregoing), in any Covered
Free Writing Prospectus, in any &ldquo;issuer information&rdquo; (as defined in Rule 433 under the Act) of the Company or
in any Prospectus together with any combination of one or more of the Covered Free Writing Prospectuses, if any, or arises
out of or is based upon any omission or alleged omission to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading, except, with respect to such Prospectus
or Permitted Free Writing Prospectus, insofar as any such loss, damage, expense, liability or claim arises out of or is based
upon any untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information
concerning such Underwriter furnished in writing by or on behalf of such Underwriter through the Representative to the Company
expressly for use in, such Prospectus or Permitted Free Writing Prospectus or arises out of or is based upon any omission
or alleged omission to state a material fact in such Prospectus or Permitted Free Writing Prospectus in connection with such
information, which material fact was not contained in such information and which material fact was necessary in order to make
the statements in such information, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Underwriter severally agrees to indemnify, defend and hold harmless the Company, its directors and officers and any person
who controls the Company within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and the successors
and assigns of all of the foregoing persons, from and against any loss, damage, expense, liability or claim (including
the reasonable cost of investigation) which, jointly or severally, the Company or any such person may incur under the Act,
the Exchange Act, the common law or otherwise, insofar as such loss, damage, expense, liability or claim arises out of or
is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in, and in conformity
with information concerning such Underwriter furnished in writing (including via electronic communication) by the
Representative on behalf of such Underwriter to the Company expressly for use in, the Registration Statement (or in the
Registration Statement as amended by any post-effective amendment thereof by the Company), or arises out of or is based upon
any omission or alleged omission to state a material fact in such Registration Statement in connection with such information,
which material fact was not contained in such information and which material fact was required to be stated in such
Registration Statement or was necessary to make such information not misleading or (ii) any untrue statement or alleged
untrue statement of a material fact contained in, and in conformity with information concerning such Underwriter furnished in
writing (including via electronic communication) by or on behalf of such Underwriter through the Representative to the
Company expressly for use in, a Prospectus or a Permitted Free Writing Prospectus, or arises out of or is based upon any
omission or alleged omission to state a material fact in such Prospectus or Permitted Free Writing Prospectus in connection
with such information, which material fact was not contained in such information and which material fact was necessary in
order to make the statements in such information, in the light of the circumstances under which they were made, not
misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any action, suit or proceeding (each, a &ldquo;<B><I>Proceeding</I></B>&rdquo;) is brought against a person
(an &ldquo;<B><I>indemnified party</I></B>&rdquo;) in respect of which indemnity may be sought against the Company or an
Underwriter (as applicable, the &ldquo;<B><I>indemnifying party</I></B>&rdquo;) pursuant to subsection (a) or (b),
respectively, of this Section 7, such indemnified party shall promptly notify such indemnifying party in writing of the
institution of such Proceeding and such indemnifying party shall assume the defense of such Proceeding, including the
employment of counsel reasonably satisfactory to such indemnified party and payment of all fees and expenses; provided,
however, that the omission to so notify such indemnifying party shall not relieve such indemnifying party from any liability
which such indemnifying party may have to any indemnified party or otherwise. The indemnified party or parties shall have the
right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense
of such indemnified party or parties unless the employment of such counsel shall have been authorized in writing by the
indemnifying party in connection with the defense of such Proceeding or the indemnifying party shall not have, within a
reasonable period of time in light of the circumstances, employed counsel to defend such Proceeding or such indemnified party
or parties shall have reasonably concluded that there may be defenses available to it or them which are different from,
additional to or in conflict with those available to such indemnifying party (in which case such indemnifying party shall not
have the right to direct the defense of such Proceeding on behalf of the indemnified party or parties), in any of which
events such fees and expenses shall be borne by such indemnifying party and paid as incurred (it being understood, however,
that such indemnifying party shall not be liable for the expenses of more than one separate counsel (in addition to any local
counsel) in any one Proceeding or series of related Proceedings in the same jurisdiction representing the indemnified parties
who are parties to such Proceeding). The indemnifying party shall not be liable for any settlement of any Proceeding effected
without its written consent, such consent not to be unreasonably withheld, but, if settled with its written consent, such
indemnifying party agrees to indemnify and hold harmless the indemnified party or parties from and against any loss or
liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an indemnified party shall
have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by
the second sentence of this Section 7(c), then the indemnifying party agrees that it shall be liable for any settlement of
any Proceeding effected without its written consent if (i) such settlement is entered into more than 60 business days after
receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall not have fully reimbursed the
indemnified party in accordance with such request prior to the date of such settlement and (iii) such indemnified party shall
have given the indemnifying party at least 30 days&rsquo; prior notice of its intention to settle. No indemnifying party
shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened
Proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought
hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from
all liability on claims that are the subject matter of such Proceeding and does not include an admission of fault or
culpability or a failure to act by or on behalf of such indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the indemnification provided for in this Section 7 is unavailable to an indemnified party under subsections (a) and (b) of this
Section 7 or insufficient to hold an indemnified party harmless in respect of any losses, damages, expenses, liabilities or claims
referred to therein, then each applicable indemnifying party shall contribute to the amount paid or payable by such indemnified
party as a result of such losses, damages, expenses, liabilities or claims (i) in such proportion as is appropriate to reflect
the relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering of the
Shares or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate
to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one
hand and of the Underwriters on the other hand in connection with the statements or omissions which resulted in such losses, damages,
expenses, liabilities or claims, as well as any other relevant equitable considerations. The relative benefits received by the
Company on the one hand and the Underwriters on the other hand shall be deemed to be in the same respective proportions as the
total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by the
Company, and the total underwriting discounts and commissions received by the Underwriters, bear to the aggregate public offering
price of the Shares. The relative fault of the Company on the one hand and of the Underwriters on the other hand shall be determined
by reference to, among other things, whether the untrue statement or alleged untrue statement of a material fact or omission or
alleged omission relates to information supplied by the Company or by the Underwriters and the parties&rsquo; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable
by a party as a result of the losses, damages, expenses, liabilities and claims referred to in this subsection shall be deemed
to include any legal or other fees or expenses reasonably incurred by such party in connection with investigating, preparing to
defend or defending any Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
that does not take account of the equitable considerations referred to in subsection (d) above. Notwithstanding the provisions
of this Section 7, no Underwriter shall be required to contribute any amount in excess of the amount by which the total price
at which the Shares underwritten by such Underwriter and distributed to the public were offered to the public exceeds the amount
of any damage which such Underwriter has otherwise been required to pay by reason of such untrue statement or alleged untrue statement
or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters'
obligations to contribute pursuant to this Section&nbsp;7 are several in proportion to their respective underwriting commitments
and not joint. The indemnity and contribution agreements contained in this Section 7 and the covenants, representations and warranties
of the Company contained in this Agreement shall remain in full force and effect regardless of any investigation made by or on
behalf of any Underwriter, its partners, directors or officers or any person (including each partner, director or officer of such
person) who controls any Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, or by or on
behalf of the Company, its directors or officers or any person who controls the Company within the meaning of Section 15 of the
Act or Section 20 of the Exchange Act, and shall survive any termination of this Agreement or the issuance and delivery of the
Additional Shares to be sold by the Company pursuant hereto. The Company and each Underwriter agree promptly to notify each other
of the commencement of any Proceeding against it and, in the case of the Company, against any of its officers or directors in
connection with the issuance and sale of the Shares, or in connection with the Registration Statement, the Basic Prospectus, any
Preliminary Prospectus, the Prospectus or any Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.78in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information
Provided by the Underwriters</U>. The Company and the Underwriters acknowledge that, for purposes of this Agreement, the statements
set forth in the section entitled &ldquo;Price Stabilization and Short Positions&rdquo; under the heading &ldquo;Underwriting&rdquo;
in the Preliminary Prospectus dated September 28, 2016 and the Prospectus constitute the only information furnished in writing
to the Company by any Underwriter through the Representative expressly for use in the Registration Statement, the Disclosure Package
or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
In all dealings hereunder, the Representative shall act on behalf of each of the Underwriters, and the parties hereto shall be
entitled to act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by the Representative
on behalf of the Underwriters. Except as otherwise herein provided, all statements, requests, notices and agreements shall be
in writing or facsimile and, if to the Underwriters, shall be sufficient in all respects if delivered or sent to H.C. Wainwright
&amp; Co., LLC, 430 Park Avenue, New York, New York 10022, Attention: Edward Silvera with a copy (which shall not constitute notice) to Lowenstein
Sandler LLP, 1251 Avenue of the Americas, New York, New York 10020, Attention: Steven M. Skolnick, Esq. (fax no.: 973-597-2477);
and if to the Company, shall be sufficient in all respects if delivered or sent to the Company at the offices of the Company at
275 Madison Avenue, 7<SUP>th</SUP> Floor, New York, NY 10016, Attention: Sandesh Seth with copies (which shall not constitute
notice) to The Matt Law Firm, PLLC, 1701 Genesee Street, Utica, NY 13501, Attention: Thomas Slusarczyk, Esq. (fax no.: 315-624-7359).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law; Construction</U>. This Agreement and any claim, counterclaim or dispute of any kind or nature whatsoever arising out
of or in any way relating to this Agreement (&ldquo;<B><I>Claim</I></B>&rdquo;), directly or indirectly, shall be governed
by, and construed in accordance with, the laws of the State of New York. The section headings in this Agreement have been
inserted as a matter of convenience of reference and are not a part of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Submission
to Jurisdiction</U>. Except as set forth below, no Claim may be commenced, prosecuted or continued in any court other than in
the United States District Court located in the Borough of Manhattan in the City of New York in the State of New York, which
court shall have jurisdiction over the adjudication of such matters, and the Company consents to the jurisdiction of such
court and personal service with respect thereto. The Company hereby consents to personal jurisdiction, service and venue in
any court in which any Claim arising out of or in any way relating to this Agreement is brought by any third party against
any Underwriter or any indemnified party. Each Underwriter and the Company (on its behalf and, to the extent permitted
by applicable law, on behalf of its stockholders and affiliates) each waive all right to trial by jury in any action,
proceeding or counterclaim (whether based upon contract, tort or otherwise) in any way arising out of or relating to this
Agreement. The Company agrees that a final judgment in any such action, proceeding or counterclaim brought in any such court
shall be conclusive and binding upon the Company and may be enforced in any other courts to the jurisdiction of which the
Company is or may be subject, by suit upon such judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Parties
at Interest</U>. The agreement herein set forth has been and is made solely for the benefit of the Underwriters and the Company
and to the extent provided in Section 7 hereof the controlling persons, partners, directors and officers referred to in such Section
7, and their respective successors, assigns, heirs, personal Representative and executors and administrators. No other person,
partnership, association or corporation (including a purchaser, as such purchaser, from any of the Underwriters) shall acquire
or have any right under or by virtue of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fiduciary Relationship</U>. The Company hereby acknowledges that the Underwriters are acting solely as underwriters in connection
with the purchase and sale of the Company&rsquo;s securities. The Company further acknowledges that the Underwriters are acting
pursuant to a contractual relationship created solely by this Agreement entered into on an arm&rsquo;s length basis, and in no
event do the parties intend that the Underwriters act or be responsible as a fiduciary to the Company, or its management, stockholders
or creditors or any other person in connection with any activity that the Underwriters may undertake or have undertaken in furtherance
of the purchase and sale of the Company&rsquo;s securities, either before or after the date hereof. The Underwriters hereby expressly
disclaim any fiduciary or similar obligations to the Company, either in connection with the transactions contemplated by this
Agreement or any matters leading up to such transactions, and the Company hereby confirms its understanding and agreement to that
effect. The Company and the Underwriters agree that they are each responsible for making their own independent judgments with
respect to any such transactions and that any opinions or views expressed by the Underwriters to the Company regarding such transactions,
including, but not limited to, any opinions or views with respect to the price or market for the Company&rsquo;s securities, do
not constitute advice or recommendations to the Company. The Company and the Underwriters agree that the Underwriters are acting
as principal and not the agent or fiduciary of the Company and no Underwriter has assumed, and none of them will assume, any advisory
responsibility in favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective
of whether any Underwriter has advised or is currently advising the Company on other matters). The Company hereby waives and releases,
to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any breach
or alleged breach of any fiduciary, advisory or similar duty to the Company in connection with the transactions contemplated by
this Agreement or any matters leading up to such transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Agreement may be signed by the parties in one or more counterparts which together shall constitute one and the same agreement
among the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon the Underwriters and the Company and their successors and assigns and any
successor or assign of any substantial portion of the Company&rsquo;s and any of the Underwriters&rsquo; respective businesses
and/or assets.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[The
Remainder of This Page Intentionally Left Blank; Signature Page Follows]&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding among the Company and the several Underwriters, please so indicate in the
space provided below for that purpose, whereupon this Agreement and the Underwriters&rsquo; acceptance shall constitute a binding
agreement among the Company and the Underwriters, severally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ACTINIUM PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0 0 1.5pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;Executive
    Chairman</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acting
individually and as the Representative</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
the Underwriters named in</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
attached <U>Schedule A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0 0 1.5pt; width: 4%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; width: 36%; text-indent: 0">/s/ Edward Silvera</TD>
    <TD STYLE="padding: 0 0 1.5pt; width: 60%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Edward Silvera</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;Head of Investment Banking</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Schedule
A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
of Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-decoration: underline; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Name
    of Underwriters</U></FONT></TD>
    <TD STYLE="padding: 0; text-decoration: underline; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Number
    of Firm Shares</U></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC</FONT></P></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,600,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jones Trading Institutional Services LLC&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;400,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0 0 0 30pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0">Total</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center">8,000,000</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Schedule
B</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permitted
Free Writing Prospectuses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Schedule
C</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Firm
Shares: 8,000,000 shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
Shares: 1,200,000 shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
offering price per share: $1.25 per share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
discounts per share: $0.075 per share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>f8k092816ex5i_actinium.htm
<DESCRIPTION>OPINION OF THE MATT LAW FIRM, PLLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;Exhibit
5.1</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><IMG SRC="eximg_002.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
29, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
Madison Avenue, 7th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
have requested our opinion, as special counsel to Actinium Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
with respect to certain matters in connection with the offering by the Company of up to 9,200,000 shares of its common stock, par
value $0.001 (the &ldquo;<B>Shares</B>&rdquo;), pursuant to the Registration Statement on Form S-3 (No. 333-194768) (the &ldquo;<B>Registration
Statement</B>&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) under the Securities
Act of 1933 (the &ldquo;<B>Act</B>&rdquo;), the prospectus included within the Registration Statement dated April 18, 2014 (the
&ldquo;<B>Base Prospectus</B>&rdquo;), and the prospectus supplement dated September 29, 2016, filed with the Commission pursuant
to Rule 424(b) of the Rules and Regulations of the Act (the &ldquo;<B>Prospectus Supplement</B>&rdquo;). (The Base Prospectus
and Prospectus Supplement are collectively referred to as the &ldquo;<B>Prospectus</B>.&rdquo;). The Shares are to be sold by
the Company as described in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have examined and relied upon the Registration Statement and the Prospectus, the Company&rsquo;s Certificate of Incorporation
and By-laws, as currently in effect, and the originals or copies certified to our satisfaction of such records, documents, certificates,
memoranda and other instruments as we have deemed relevant in connection with this opinion. We have assumed the genuineness and
authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies,
and the accuracy, completeness and authenticity of certificates of public officials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are licensed to practice in the State of New York. This opinion letter is limited to New York law, the Delaware General Corporation
Law and applicable federal law of the United States. We are not rendering any opinion as to compliance with any federal or state
antifraud law, rule or regulation relating to securities or to the sale or issuance thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the foregoing, and in reliance thereon, and subject to the qualifications herein stated, we are of the opinion that
the Shares, when issued and sold in accordance with the Registration Statement and the Prospectus, will be validly issued, fully
paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the reference to our firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus and to the filing of this
opinion as an exhibit to a Current Report on Form 8-K to be filed with the Commission for incorporation by reference into the
Registration Statement. In giving this consent, we do not admit that we are &ldquo;experts&rdquo; within the meaning of Section
11 of the Securities Act or within the category of persons whose consent is required by Section 7 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 40%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Matt Law Firm, PLLC</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    The Matt Law Firm, PLLC</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>f8k092816ex99i_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED SEPTEMBER 28, 2016
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;99.1</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="eximg_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actinium
Announces Proposed Public Offering of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEW
YORK, NY &ndash; September 28, 2016</B> &ndash; Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (&quot;Actinium&quot; or &quot;the
Company&quot;), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced
cancers, announced today that it intends to offer shares of its common stock in an underwritten public offering. The offering
is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. is acting as sole book-running manager for the offering.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering is being conducted pursuant to a shelf registration statement that was previously filed with, and declared effective
by, the U.S. Securities and Exchange&nbsp;Commission (&quot;SEC&quot;). Prospective investors should read in their entirety the
prospectus supplement and the accompanying prospectus and the other documents that Actinium has filed with the SEC for more complete
information about Actinium and the offering.&nbsp;A preliminary prospectus supplement and accompanying prospectus relating to
the offering will be filed with the SEC and will be available free of charge on the website of the SEC at&nbsp;<U>www.sec.gov</U>.
When available, electronic copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained
from the offices of H.C. Wainwright &amp; Co., LLC by emailing <U>placements@hcwco.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Actinium Pharmaceuticals </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc. (<U>www.actiniumpharma.com</U>) is a New York-based biopharmaceutical company developing innovative targeted
payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on
its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta
emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate
Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred
to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory
or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product
candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the
age of 60 in a single-arm multicenter trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release contains &quot;forward-looking statements&quot; as defined in the Private Securities Litigation Reform Act of 1995,
including statements regarding the proposed offering. These statements are based on management's current expectations and involve
risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking
statements may include statements regarding product development, product potential, or financial performance. No forward-looking
statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes
no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actinium
Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
O'Loughlin</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Finance and Corporate Development</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>soloughlin@actiniumpharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>f8k092816ex99ii_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED SEPTEMBER 29, 2016
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex99ii_001.jpg" ALT="" STYLE="height: 157px; width: 648px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Actinium
Announces Pricing of Public Offering of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEW
YORK, NY &ndash; September 29, 2016</B> &ndash; Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (&quot;Actinium&quot; or &quot;the
Company&quot;), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced
cancers, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to
the public of $1.25.&nbsp;In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 1,200,000
shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about October 4, 2016,
subject to customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to Actinium from this offering is expected to be $10,000,000, before deducting underwriting discounts and commissions
and other estimated offering expenses payable by Actinium. Actinium currently intends to use the net proceeds from the sale of
securities for general corporate purposes, including capital expenditures, the advancement of its drug candidates in clinical
trials, such as Iomab&trade;-B and Actimab&trade;- A, preclinical trials, and to meet working capital needs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. is acting as sole book-running manager for the offering.&nbsp;JonesTrading Institutional Services LLC is
acting as co-manager for the offering. Roth Capital is acting as a financial advisor for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering is being conducted pursuant to a shelf registration statement that was previously filed with, and declared effective
by, the U.S. Securities and Exchange&nbsp;Commission (&quot;SEC&quot;). Prospective investors should read in their entirety the
prospectus supplement and the accompanying prospectus and the other documents that Actinium has filed with the SEC for more complete
information about Actinium and the offering.&nbsp;A prospectus supplement and accompanying prospectus relating to the offering
will be filed with the SEC and will be available free of charge on the website of the SEC at&nbsp;<U>www.sec.gov</U>. Electronic
copies of the preliminary prospectus supplement and accompanying prospectus and, when available, the prospectus supplement and
the accompanying prospectus may also be obtained from the offices of H.C. Wainwright &amp; Co., LLC by emailing <U>placements@hcwco.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Actinium Pharmaceuticals </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc. (<U>www.actiniumpharma.com</U>) is a New York-based biopharmaceutical company developing innovative targeted
payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on
its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta
emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate
Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred
to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory
or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product
candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the
age of 60 in a single-arm multicenter trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release contains &quot;forward-looking statements&quot; as defined in the Private Securities Litigation Reform Act of 1995,
including statements regarding the closing of the offering and the anticipated use of proceeds. These statements are based on
management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from
those set forth in the statements. The forward-looking statements may include statements regarding product development, product
potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from
those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as
a result of new information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actinium
Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
O'Loughlin</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Finance and Corporate Development</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>soloughlin@actiniumpharma.com</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>eximg_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 eximg_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "! L,# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_:]_#/>37%S;RQPS);P@'Z@T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %)D9QD9()QWP, GZ D?G7XEZSH7BCQ?_ ,%<? G[
M,VB?%[]H!_A3\(?V&_BY^TE\=%@^-WCW3[;QQ\3OVC/CM8^ ?@9I/B2P\/ZW
MI.F6T'P\T'P!\9=9\!Z)I>FZ-I7ARS.C+:64T-O!L_+'X4_M@?&+]F[]M#]L
M/XZ^ [9_CG\.OC;_ ,%9_P!C_P#X) _#[1?BG\1_B;XG\6V<'P6^$=Y9_M#>
M./!2*-2T'1]3C\2W7BWXD>.-5MM-31O$7B/2-8@FTBSG2VN;@ _L#HK\6_\
M@F=_P4[^.'_!1'Q/IGQ#L/V4-7^'O[''Q0^'_P 6/&_P;^-FL:U;VVM&[^&G
MQOE^%6@^%?$FBW-[*?$VK_$;PQ%<?$2ZO?"-A;>'_A?=:?-X!U?6?%VJWEOK
M,?Q3^UW^U_\ &;]EW_@L#\$?C[K7Q;^)</[!^O\ Q/N/^">'Q)^">CZWXX\5
M^$M8_:%\1?LRP?M!?#[Q_P"&/AS9R:GITWC_ %WQ+XJ\'_"73M)\-Z,EQJ6H
MZ%?JLD>LZAK+70!_3U17\DGPN_;D_:6\+_MB?\%+OVB_CS\:(&A^'GQC_90_
M8<_8W_94UOXG?%>T_9]M_P!J3XT>$!XN\=_!O1O!7P<\-^/-4^,OQN\ ^%M3
ML-*OVL? NNZGX[^)&D^+E\-WO@GPO=>']8\,]E\3?^"O_P"V5\7/A%XA^%/P
M:\)_#OX0?'SQ+_P5M\#_ /!*OPE\4]:\-^(I+74X=:\+P^+_ (O?$G0?A?<^
M--6U/P1XK^"^B_;;'Q+#JOC3QII-O,+>?3KN#Q+=VFBZ< ?U4T5^-7[!'[2G
M[5_[3G[;7_!0:+QKXQ^$-[^S)^R7\1?!_P"R'X3T7P#X4\7:==Z_\;/"/@O3
MOB!\:O%9U+6O&FLK!J.EZ]X]T3P+JFG7]IJ4,&G>&M+CT5]-O9/$>H>(O-?@
M/\1?&'Q:_P""U_\ P4=\2:Q\9/BCH?[,'["_P'_9Q^'K^!+[XO>-=+_9_D^.
M/Q-\$:U\2?B'\1M4\(S>(K7P)!J/@;X;P:7X?UNUU&Q&A:9=7A\7W5DOB,IK
M<0!^[]%?S\_';_@LSXL\$?M >#O"OP3\$?#+X^?!GQ)_P4"^#/\ P3V34O!$
MGQ+N]<N_BAX[L]WQ2AO/B5JVA^%_AKX>\=_!R>/5]0U#X:^&=-^+6GW?ASP]
M+J?BOXC_  ]N-<LK*Q\"?_@NY\:O#?QL3X7>.OA/\);;2?"'_!3+]H#]A;XO
MZ[X>A\;WEQX6\/\ @[PEJ'B+]F:;2+2]\2VTVI?&']J_4O!WC[P[\//"BVEQ
MI1O],L9;AH8+G37UX _J#HK\0O\ @K[\??VA?@1_P1E^,'Q%US4+CX??M@>)
M?!/PB\!^'4_9X\8>+/#%SX;_ &@_BW\1_ _@[1]-^&OBFTU>/Q/?P>&=9\02
MN[F^*^*M+T;48[JR&F:G-IZ_)?[3_B'X[?L9_P#!//\ :C^/OQ/\$_M'0^,?
MA1\-?"_[)-M\//'7[=GQV^(4?[5]Y^T3IW[/'@35?C9I.NZ3J/BNY^&7Q3TO
MXB>--:\._"WQ#\+)_#^IZ)J?_">KJ-WIJ7VFR>'P#^G&BOQ(^ G[4/[6FO\
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M8ZEX3^*OBCPM(;O5?%MYI_B7X3:=XL\%P6.N>'M+GNP#] ;_ /9*_9DU*_\
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M\17OB'4-;ATNSM(HK.+4KGQ7<W?B,W,4(2-H-7G:[M%5;1DA2!(8P#MZ***
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MI?#WQ'\/_P!I?QMX9_9_^"<'BS]IRT\030J[Z[+8VND0_#/2SI0O-%UCP_\
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MI:E:Z-?21ZEK=IHWBSP];6'B+PN-9OVTBZCMKF\LKH _H7_:.Y_9Y^//&?\
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M42>$O#Q.A>''UF[22];1M()T^P,OV>U/E(M=O0 4444 %%%% !1110 4444
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MO$-GIFJZM_8<4J:=?:K=:;IBWU];7-U!865O)% @!XK_ ,-E>%?^B%_M?_\
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MJQ:TU&SNK.8)<6\L:=30!\@?\-E>%?\ HA?[7_\ XBK\9?\ YF:/^&RO"O\
MT0O]K_\ \15^,O\ \S-?7]% 'R!_PV5X5_Z(7^U__P"(J_&7_P"9FC_ALKPK
M_P!$+_:__P#$5?C+_P#,S7U_10!\@?\ #97A7_HA?[7_ /XBK\9?_F9H_P"&
MRO"O_1"_VO\ _P 15^,O_P S-?7]% 'R!_PV5X5_Z(7^U_\ ^(J_&7_YF:/^
M&RO"O_1"_P!K_P#\15^,O_S,U]?T4 ?('_#97A7_ *(7^U__ .(J_&7_ .9F
MC_ALKPK_ -$+_:__ /$5?C+_ /,S7U_10!\@?\-E>%?^B%_M?_\ B*OQE_\
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MA?[7_P#XBK\9?_F9H_X;*\*_]$+_ &O_ /Q%7XR__,S7U_10!\@?\-E>%?\
MHA?[7_\ XBK\9?\ YF:/^&RO"O\ T0O]K_\ \15^,O\ \S-?7]% 'R!_PV5X
M5_Z(7^U__P"(J_&7_P"9FC_ALKPK_P!$+_:__P#$5?C+_P#,S7U_10!\@?\
M#97A7_HA?[7_ /XBK\9?_F9H_P"&RO"O_1"_VO\ _P 15^,O_P S-?7]% 'R
M!_PV5X5_Z(7^U_\ ^(J_&7_YF:/^&RO"O_1"_P!K_P#\15^,O_S,U]?T4 ?(
M'_#97A7_ *(7^U__ .(J_&7_ .9FC_ALKPK_ -$+_:__ /$5?C+_ /,S7U_1
M0!\@?\-E>%?^B%_M?_\ B*OQE_\ F9H_X;*\*_\ 1"_VO_\ Q%7XR_\ S,U]
M?T4 ?('_  V5X5_Z(7^U_P#^(J_&7_YF:/\ ALKPK_T0O]K_ /\ $5?C+_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<UXR\4V/@?P
MGXC\8ZG8Z]J>G^&-%U'7+O3?"V@:OXK\3:C#IMK+=-8>'O#&@6E_K?B#6KWR
MQ:Z7HVDV5U?ZC>RPVMK#)+*JGI:\_P#B5I_Q$U+P_;0_#/5/!NG:Y'KVA3ZI
M;>.]$U76=!\0>$8[^-?%GAH2Z-JNFWV@:IK.B/=VVC>)E@UVWT34_LUU>^&M
M=L_/L) #PYOVQ/AO;^&=5\1:CX9^)&GW6@_'GX;_ +-VN>%AX<TW6O$6D?%+
MXIO\-5\-:9>OX8U_7?#JZ;;'XK^$4\2:K#XAFM_#-X=9TK61::QH6I:?!W.@
M_'6V\5_%3Q#\,_"WPY\?:YIOA#59M"\6?%2VF^'\'PXT37;72(-4N=$<7GCN
M#X@ZAJ-M/=V^C2OIO@&ZTM=974;(:H6T;5FL_F/PI^QKXS\(6?P"\-VWB?PI
MJ?@;P+^U#\0?VH_B!X7N6\06NE:;J_BS3_B'=^&?AW\(--2"\33/!'@3QSX\
M@\<V*>([V:YU'7O#JW<4.D)K(M-'ZOP'^S5\4- ^*OA[XX>(-4^",'Q"\.^%
MO$G@"ZMOAKX!U[X?^$O&]A\4OBSX(\>?&7XF>+]-@U[4]0O_ !]KFC> ]&A\
M#Z/JNI^(M/\ !_BF]\7ZW?>)?$B>,[N#2P#TZU_:K\":IXO\2^&?#GA+XJ>,
M-*\'ZM\0O#?B7Q[X-\"7OBGP?I/B[X8:3=ZIXM\*RQ:+<WGC&XU.&ZTW5O"F
MDWUCX1NO#FO_ ! TC4_AYHNNWWC6SDT(84'[:OP6L_#/QY\4>.7\4_"VU_9J
ML/#6H_%VP\?Z+!9ZCX?C\8> ].^(_AO3[8:#J7B&PU?Q+J7AK5M.(\':9?W/
MBZTU2]L-*O=#M[O5-*2^^6=*_8.^,?PYT.RO?A'\1OA]HWQ(\%^#?BO\/?"'
MC*_TWQ)9:WXRL/CU\;O#7Q2^*_Q"^)GBVW_M?Q WQ#ET3P_/IG@>VL(]6\+^
M$O&NO:QXW-GJ5J-$\+Z%M_$_]ACX@_$?]FIOAAIGB3P9\,?'NIS>+M/UW3O
M^J^++SX7ZIHWQ'U'2M&^('B3Q9>^,=*\2>/OB7\7]9^&=IKOAZR^*'B>]L_$
M6GZUXRUO5!<S1Q!+T ^KOB)^TUHGP]^#_A?XU-\,_BUXK\,>(_"47CS4-/\
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MNZG?66L:I;SW+QW]RLM'P[^RY\ _"4-Y#X8^&^E:$MY.DHDTR_UVTN=-@'Q
M7XJ3Z3X?NXM5%UX9\.ZA\0U'BW5_"_AV;2_#NMZL6DU?2[V-VB(!\8^$_P!K
M[QSXW^+<=[?>++3X6?"K6?&G[4FC_#$^(? VA:UX \>?#_\ 9=TO6/!OC+QC
MXM\6W'C7P[\1?!>I-\4(I/'6G>)8/#I^&5W\*_#D/A+[3_PEGB[2?%=8.I_M
ME?%CX(?#+XP?$OXIZQX9\5Z#=>!H_$/[,4WCO05^"NN?$_4_ 7@37/%?QO\
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>eximg_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 eximg_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "= H@# 2(  A$! Q$!_\0
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M668YK[&K#)\HC*:>-QKIR]C[>4-:.#H5'2JXNI>$Y48RH8>3KUH*/Z.^ ?\
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M3?#MN\D\Z!P#M&X @C.1S@'GU./QZ_R_?\'!?[;WQ \ _LZ^ _AAX"U>_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3C_*Z=-K3R<&NG8\G\$?!SP;X$T*'0]'TZ!(8HU0N(D!;:NW@;0 -O
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M1<-<*XK#8W,L)%8?!K%XRK@LFE0Q5#%X.>7U)X*K6J4_J:BOPL_9N_X*._M
M?&KQG\8%T'X2:E\1O$FJ1>$H/A)\*/#)M=)\%^!M-A_MQ=>\2_$#XDZE;1/;
M6]P[Z0;B>[9IM5N,6?A_2;..*=EL?$+_ (*(?M?_ ++_ ,3_  [H?[4_P6^&
M]KX/\40?VK /A]J.HW%[%H45TMMJEQHNOSZOJFGZKJ>AM+&;S2=2TW2Y9PT&
MR>W2[AG/-4\ _$*&>8SAETN'EQ'A,!#,(9#4XGR>CF^84EE]/,L3#*L!4K2K
M8Z6#HS=.K4YL'AZU:C7C@JN,ITI5UVX?Z7?@[B.%<!QRJO&2X+QV<U<FK<5P
MX'X@Q'#V3UO[7J9-@\1Q!FU&BL+E%',:\(8C#TI_7\90PF(PM3,:& K8B&#/
MVWURVO;S1=7L],OSI>I7>F7UKI^IB,2G3KZXM98;2_$1XE-I</'<",\.8]O>
MORH_8#_9=_:X^!WQ5^)OB3X[_$.36_"&M64]C:::WC;4/&2^,_$4FJ0W,/C<
M6^H-(WAX0645W'LD^RZC<-J7V.:U%M90R-]M_&7XG_%O0_AGI7CO]G[X9:+\
M9+K4[!=;>QUGQE!X*CM_#5QHTFK6>L6AN+&Y.LW4I%O%_8Z7&G3,LY<7091&
MWY]_\$ZOVS/C7^U-\;_B[#\2M1TJV\-Z9X$TG6/#'@OP[I5K9Z)X?N?^$BCL
M+F:.]F2XU[4+R>"Y6.:;4M2GB?:3!;6P4+4<(91QI#PR\4,QRJCPE+AB.#R^
MEQ5+-(97C>)\%+"9KAJ&%H97AYTJN:917Q&)JR2KU)8;#UZ>'Q52A4EB*29I
MXD\1>&%?QK\!LHS[%<?PXVJ9KFV+X _L&>=9;P3F<,PX?Q6*QV(S_'1JX?),
M^PF'P.'ISC@L/]<QU&KB\)2Q-&&!KSC+]E**_'K]LO\ ;P_:<_9%\;6>E:M\
M+_@MK_A+QA-XBO?A]JEKXC\92:Q<:'H=Q:1;?$]D;:PAT_6%2_LS/'8&ZL9'
MDD$%RPA85^B'C/7_ (WZA\-O#&O?!?1?AOJ?CC5K70-4U+2_B1K'B'2/#D&F
M:CI'VW4([&^\.Z;J=])J45W);0V4=S#':- T\L\RLL:M\=F/ 6?Y5E7"V>8^
M63T<FXQGBJ>1YHL[P-7!U98%4_KGURI3IRGET<+.K&E7EBZ$5"LITK2E%R?Z
M3DWB_P (9_G_ ![PIE5+B7$\3>&U' 5^*<A?#&8TLSI4LT=;^RY970JXF-/.
M/[1I4)XG!K!8J/ML+*E7_=JK&FO=:*_*3]AK]OKXE?M2_%SQW\-?&W@'P7X1
MA\'>$;_7#>^&-1UJ]GFU33_$>FZ%-9O_ &H[Q-:,+R>19(D27?"G 60A>%_;
M>_X**_'+]G?Q!K?P]\/? 63PG<7SZE;>"?BQXYU2'6/#OB.TLTA637_#6AZ1
M"EK<M;M=V[MIVL:Q%<V4C1_VCIK12*K?08?P9X_Q/&L?#Z&79='B=X#!9H\)
M4S[**=#^SL?0ABJ&*IXJ>)A#%+ZM-8BI0P-+&8NG14JCPK@G*/R6)^DUX1X3
MPQK>+U3-L[?!%'.,RX?>-I\*<05,;_;.58J>!Q6!K9=3PM6M@6\?!X*CBLSK
MY=@:F*<:/UM5)1IS_96BORHE_:*_;[^(OPX\)^+_ ( _L^>%I]%?P=HFHW_B
MOXLZI;:+XC\?:L=%M;G5M3\'?#NSUK1GTW0=0O3<'0I=8U*WN-4B,5Q;6=K:
MS0"3SSX!_P#!577/'UAXD\">-/@CKVH_M#:9='2_!_P_^'=O>/:^/-7BFFL]
M1L+Q]8,S^ F\-SV\MWXFO=<N[G3;'38[FXAN7GM_L4DT_!WC;%9;F>99=2R+
M-UD>+6%SW+\JXFR/&9MD:EB:V%CC,XP$<72> P"J4*DJV,JXV=+!TXSGCI83
MV=:%)U/I*^%V#SC(LGSBMQ7P]_K5@7C>%,WS[@CB;+<@XIJ1P&'S&66\.9K/
M!5UF^;.AB:5/#8##9=2K9CB)0HY8L;[;#5<1^S5%?B7\;?VUO^"@O[-LWA_Q
MQ\8O@#\(+#X:Z]JD6F)8^'M>U36Y[*[>)KI-&U'Q59ZS<C3M;NK2&Z:SFN/#
MCZ9<RV\R0^8T31']6O@A\8?#/QX^%7@SXL^$A=1:'XQTH7\=G?"-;[2KR">6
MRU32+X1;XC=Z5J-M=6,[Q,8I6A,L7R.E>-Q+X=\2<+Y)E7$F+>39EP_G&*KX
M#!YQP[GN79]E\<SPL7.OEF)KX%P^JXZG",I>RJTN2<8MTJ]73F^DX*\:>">.
MN*<]X(RZ/$F2\8<.X##9QCN&^,>&,UX3S>KD6-J>RPN>X#"YJY_7LKK3<8JM
M2K1K4G.'M\)1?.J7K5%(.0#_ )_3%+7PQ^LA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!5DN8X8C-+(J1@<NY"@'''.,=<Y[=*H#7](/34K3Z>?'^7(S_6OYX/V^OVMO
M$/P9_;[U'X<>+?$'C.;X+ZO\(?AM?RZ1H'B?Q!I(\)Z[?ZAXMBO/$-E8:/J-
MG#?VU_';VR:Y:2(\[QVT%W:OYMN8+C?M/'WPNO[6VN[?Q%XNN[2[ACN+:ZMO
MB7XL$-Q!*@>*:-U\09:-U(9<?WOF .0/VW)? WB+.LCR?/L/C::P^<X"GC\/
M"E@,5B53IU*E>FJ=2K'$1@ZL70GSQY(V3@TY)NW\1\??3<X7\/\ C_B+@''^
M'W%688GA[-*F5U,TP>:\/T\'C*E+#X.LZN'HXB,L32@UBO@Q#<X\C=WSJW]
M U_1C_S$[7T/[Z+KZ<X_S]:/[?T<Y_XF5H!C.?.C_/GVYP#VX]:_!"'QG\+4
M8,^L^,3CH'^)GC!QD$<E?^$A !R!G<#QFKW_  GWPJ'+:KXM(YZ?$7Q9G\<:
M\..O3 '&!Q4XKP.X@P=Y5LPH0C'5^TP>(I7\FGB9-=]#V\A^F%PUG_LU1X'X
MEP[J<MG5S+)9<JGJKJG!W:ZWM'SOH?I1^V'J'A_Q9\&_'?@6]OH+C3O%_A77
M_#.J6T=PB-=Z7KNE7>E:C K!B$:6SNYHU;:P#,I(K_.0\0?L%_&GX;?$35?
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M^'K>[31]+6=RHN;J6XU+4-1U"6-?+C>>"V1G%ONK^D5-=T8* -1M !T431X
MQP.IXP.!Z$>H)_GQ@\5_!7P_IZ66B3^)],MHX@J16/Q#\66R*%..%AUU%'
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MR(4VX01>7&=IBX QM&,5O?\ !*YA%^Q9\.O,.TG7_B!U&=W_ !6&JY'.>2>
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M,#G'3//8<U_;O-^WQ^S';8,]WX@B4KD%OA_XXQ@]_E\.'/&,C(Z<@<5BS_\
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MJJ@ZM)5Y4W55#VM+V[I1ER2JJC[55G24VH.HJ+IJ;4'44FHN_1114F@4444
M%%(QP"?2L_4-5T_2K<WFJ7UEIEFLD$)N]1N[>RMO.N9%AMHO/N9(XA+/,Z11
M1E]\LKI&@9V4$2;:C&,I2EI&,(RG*3[1C&,I2?E&,GY6U4SG"G&4ZDX4X0BY
M3G4G"$(15KRG.<H0C%75W*<4KJ[1HT5$)#G!4]0.F.HR,=<^GU]:EH_K\O\
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M2E!QFFM59)[NZ=^^O4_*_7_^"@EN=Q,/B,]?^7&W/8GG_3>3ZGT/OQXKK_\
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M"4K]KAN(E\MOP)_85F_:J^*?[1OQA\4_"WXJ>#[#XN7/A749O&WC3XKZ!?\
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M05"L><LC*)&.2=HYX%?;G_!8Z-'_ &6O#DC(&F@^,/A3RI& RA?0O%2N4;H
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MMITE@EDC;_3&_98^(^N?%W]G'X'?$WQ1 MKXG\=?"?X>^*_$END7D)#K^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex99ii_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99ii_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "1 E@# 2(  A$! Q$!_\0
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M>ZV:33/] IIJ<EK\36SON244@((!!R" 01T(/(/XTM62%%%% !1110 4444
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M!1.J/YD:_C3^W7_P1H_:)^'7[37C[Q#\+?"L/C/X9?$;Q#J/BO3[F&:.VO\
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MB+P'I.CZPFCE$U6X\$W'C3P]/\0](BG15G2VU#P!:^*-.D@CD,UX=:>" KC
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ML<10E!U(U:<H1I4*[G&7-'V.*H+%8:K=)ITZ^&:KTI1YE.DU-:-7MT52-_;
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M)*:AH^IVMQ<6-ZTT%U!*#)%<>>C)/:7-A+'&EQ;MN*R9F*R @Q;E85_*RO\
MP56^,7A.RT#XA6_QA\:?$?Q@+])OB)X;\4:I_:?ASQ+I0O2^KZ;I^BR6_P!G
MTN[EMYYY=-71_L\EA;B$3&?>&/\ 9%^ROX?TOXM>!O!'Q4TJUDMO#7C;PKX=
M\7:+;3QN);2SUG3;>^CM)#*0[R6QD>(R2#>Y0L>HK]AGP_A?"W)*F(QE2AB,
M55H<RK1]V.(J**FU&,DINZFE%\NJA)2L[)_D&;PSSBK/J4HSJPPDZ_-3IQG&
MU.FW!**BIW234G:VG-MK<_-[X1?\$1_@RWC>?QQ/X.\.6-G?:HFIR11::UM
MT\5Q]H2:VM-DMNDBR@B1=T89@\@9BQ%?T'^"/!5CX%\*Z3X;TE+>"'2[-;.-
M8D$5K&%*Y$%M&BI"@50$C50$"J,8Z=-8:?'96D$$(5!&JC&/EXSG&,?7C )P
M2*T0G!&>N/PP<_YZ5_/?$?%>:<2XB,L75G/!IMT:4F^6C1U]E346[I0ARQ22
M5DDK*Q^VY%DM/)L'&G!<U=PC[1O=S48\S??FE>[OW,*2\4R&+R65WV!748RS
M.\*@\G 7=N8D9QV (K^<3_@JEXMUWXH?$[6_"WA[3[S4OA[^SKI/ABP\?:U;
M3YTW2?'OQ7=EMK:2W$<NZXB\+V6F;Y!Y;65SK%Q$V43SC^_7Q&^(ND_#OP9X
MN^(6N7%M;>%_!.@Z[XDUZ\$L:M'I_ARUFU&ZA4R*-MS?)$+*W4;PD\ZR'>$9
M#^#7P9\?ZQJO[.'QJT/XC_LK_M,^.?%'[46K^*?B1XG^(7@[X<2:MX3:Z\8Q
M#4O!2>'=8FNUEETSPR73["_D(T>G"*!#'M1Z_4?!"M4X>X@?&LLLP><4LLQF
M78"A@,5C\!AZ7L\TQ=/!8[$PEB\=@XSJ8'*ZF-Q$*5*=:2KSI*I2Y9-+^6/I
M68K!\5<.99X3PXCJY++BCA[B3C7-<PR[+\QSB=++?#G#/-\DE5HY)@<VQ%.'
M$7']7):+C4P].M6RW*,UHQ@Y5*:G^D?_  3>^.C_ !L_9Q\-P:E>"]\8_#2Y
MC^'WBO=+$UQ/'HZ(-!UIH68W&-1TMEMO/E$1D^S7IC^:%%F^_IKAXT2XD"JB
M3-N)(4;=K1HH)VHIDD=44LRJ&926&"1_,3_P2Z^+UQ\&_P!I^?X7>)(KW2--
M^)&G7?@OQ!9ZFAM;O2/B%X.ESX<&L6TB@66I7+:IX@\/-8AWGFO)[:X9C%!Y
M;?N_^UY\?1^SM\!_%OQ*CMK:YU>VDT_1?"VGW3,8[[Q%JFH"SL0T4:F62.T7
MS-6DC4#S([4Q[EY>GXO>&>.RGQDQ?#O#F#K.EQGF6%?"=.HJ=+!5\/G&-]A0
MQ>%K5I1PT\)1KXB56=6-1THX=IN7+3-_HP^->#XB^CAE_&?&N.C1QOA3D.=9
M/Q[RU(3S54.$\)B*.!QF)PLG#$+,<5D.#A6PN$K4UBZF(@J/LE6J*F_>-5\4
M>%='9(]2UG2M.<3;HEU2_M;)?-8 @Q27,\*3CHIVL2&X(Q@U<LM<TC4XEGTJ
M_L=5@D;*W=G>0W5M)<.ZI$%EMI'B57#N\?F.KRB-_+#%2M?DG^P_^SGX7_:#
M^#]O^T/^TICX[?$#XLZCXQ4OXSN9=3T#PKH-AXKUOP__ &7X;T"-_P"R=(MK
MN;2A=">.S-S#!<06[SF6%Y9-W]EC]B#XH?LY?M)?$?6['Q3I\?[.7B/1M;MM
M!\,6?B._F>XGO#;?V)9+X;F@$6BR>%4_M&WCUN/4)O,MYI+6.TC>[$UO\+B.
M$>&<(^,,!B^)5@,^X<A4AC,/CJ5:G1X@Q^$QE"AB\OR#$>TY:V)@XXG$1THT
MIT,+B'"I*2@G^@91XF^(V<4O#[-*'AN\PR'Q%S%U?KF6XBE4QW#^0N%?$Y5F
M_&^'E4;H8'$X&E0<X9;#%8JEB,3A*$X4YRG ^F_C1^V-X+^&GQ=^#GP2L$L/
M$GCGXD^,+30]<T^#6#;0^"?#SQ7$UWKNKR6EMJ"I<NL*KING7#VIN&?S)9K>
M/]Y7T9XST'PC\0/!VO>$O$T6F:WX1\1:7J>C>);)KMT@NK.^B:'%Q=VD@2VE
M-G&DLLZ;VMW4! 5*D?SD?$']GKX;:+_P4I\,? VPTC41X"\5^(?"K:W:W?B/
M6K[4KZXUGPGKVKWMW)XADO6UEY9KBV5HG^VYC!$:L(P17ZJ_M!_L9?!/PW^R
MWXK\)^'8?&NBZ-\-?#/C?QGX=BL?'WBM9AKLUM!+/+K%U)J+W&N6C&SMUBLM
M2EFMX8S-&B[9I WVO$G ?"N25_":CE^>YO@<3QCE.6<04LQP^"C4J4J./S6A
MA,-C:-"EB>:$J&*E'#K"\TZZITXXE5:E62C+\]X%\3_$/C'%?2%GF7!G"&9Y
M;P+QYGG!^591BLYQ.54LTPF3\/ULQQ&78S$XS!8R%.AB*;ISQ;Q&$A3KT:\\
M-&-*$I5Z?I7[)OP;_9H^#&D>.]&_9O\ $,GBL'Q>FG>.+^]\80>+;^/7;2PB
MFM?#=YJS,?L4&E:6T/V2S$$),<J"21IYLGZIU3QIX3\,ZAHFG>(_$NDZ1K'B
MS43I.@:/J>H6MO=ZSJIMI+QK;3+::5;J^D6UAED(MX9 J02$N ,U^1'_  1X
MT^[U#X&_&>.1DL9;OX@@B[LK2&">RN;[P)H8BU"W4*4%Y"LB-$'62'[0AG92
MSG/Q-XP^%GQ#TC_@HOX)^#NH?'#QSXHU>+Q%I\N@?%/Q0++5/$?A_3O%7AG4
MI;J+2]/>-=%L]2AM4O+6._M;2+;YL,C0YC<2>AB_"Z/%?B%X@9/FG&>85:O!
M^39EG.)QN=96L5+.\-E> P>*K8FM3DZ,J%7"TZL;0GRXEPJ*.%H5I.43Y_A_
MQ\K\)>!7@=QAPWX7Y#A,NX]S7(,AAPWDF>91PQPSPQC>(N+L]R?+?[,I8/!?
M7LVHXS%4)RJU<75I\DI>UQU"*G%T_P"F5O%'AV&X73)M?T9-2*>:+$ZI8Q7O
MEMD*?LL\T4[AV 6,1QR$LP! # U>FNC)9.YA8V;HJ[YI#;LRL"DZ.2F^+:"2
M)60P'Y2S;>3^%G[>W["'PC^%?P$UCXS>!;CQG<_$KP9K>DW.H^,/$/BS5]9U
MSQ+<ZYJ>B^&K^XO;Z>X\VTFBMIDOM-BL/(L[.YA8BW9'P/LS]D"WF_:>_8?\
M!Z-\6M7\0:J;Y;G0M5UC2M<U+P_X@N;7POK\D6GW$NLZ3-;7RW,L,<,5_LE$
M=RJ2"1<RDU\/F/AYE&$X'P''N39Y.OEV*XKGPMC:>#R/#X3,L'7IX*GF3Q-"
M$L94HUZ:P\HUE2KRI7<J<8U)5E.E']?R#QAXCS+Q/SKPGXDX,X?P'$+X"J\<
M93B,+Q7B,PRK,\JGCL1E2PF,H3P>'K8*]>AB85L33IN3C1J)TO95:56IK_!W
M]G#]D'X7?M)^,?&GP[UVWN?C?XEL=;UVX\%S>-6UX>&M.UO4?M'B+4_#OAF"
M3=I$6N:A*]Y?S%GQ)<,8(HT0P#[J.IZ,K&*\O[%+J(KOA-W;VTJ!Q\J3V\TT
M4R.,'='+''-\C,592#7\Z7_!-'PW!X:_;T^,'AJPGO9['P]9_%?PS;ZCJ=S-
M>ZG>Z;X?\=W.DZ7%?7<CF2[N(K"VMTGN9G:6>;=.YW.U:G_!6?X?>&? /Q2^
M"_BKP9#<>'_$'Q.?QWK'C*^T75M7M8M=U;0;WP=!8ZG>6ZW_ )?VV-=7EV[4
M2(1AT\LADV_I/$7A=B<\\5LJX!Q7&>><0XS->",LS;!\2Y_ESI9C.E1R3$9I
M3RR=&E5C"AAL)A<,XX6I"M44ERN]27-,_'N$_'C#\$> G$OB=E7AKP]D<.&_
M$[-N%\UX/X:XCAALK3J<38+AW,<\CBIPQ$\;6H8W&X>IBH<BE#VKJ4HNESN'
M]#[7EG;A&O)[2"*5E\AIFCMHY0PC8&.ZDE2WEVJX.8YI,]4#@C+UO;*ZR;*X
MMI$78)#&8+Q(WD_U<;R033*KRK\R9;:5!)8< _)_[27PJ\#_ !+_ &?_ !'+
MX]\/VVHW?@CX8>*?$_AB9]0U&.;1M:L?"$]U9ZE#+I]]:G[3%?6]M<6SL6:!
MX0VUB.?SU_X(UB[U/X:?'BUU'5=9D>X\2>%K*"9M4O;FYMK>X\)W=JLUC=7L
MT\UO,K1&YBD4_)+(A )C);\PR[@BIB^!^(^,Z.<4?8\+9UEN1XK"58<U7$PS
M..,G0QJ:J)2]E]2K4ZL%'GCRN?,X,_=,Y\7*V3>*'!7AAC,BJ2I\=<.9UGV
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M:<?9U$N5.]U)7C/5)62MLWKW_K#F_P""77_!.J9F:;X _#5V;EI'C;#DY/\
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MR4O9G>>Y@4J!:7,RJ\UJA)VXC.2^WAI69P 6K^<'X(?\$E?!WP!\9Z#XRN=
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MN?#FC_$'5+ZSUS4H)X6CGMKF]TVQG\-6EU!(D\5]XAMO+<%L'^+6V_:;UH^
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MMB\-:9>;=JLA%GXW\(W$;8(QF-XS(AVDK( P.0:_+W_@FA\<?A7\!/A/\?\
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MR2XA66>^TJ^TS3FECGN%D1VGNUD1&E4AQ*6;R@2R?I3X0^%?PV^'T=W+X#\
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M+>[:^N+WPDMGX?L+]].DN)X]'BMK]IK@Q6T]Q:M S3>N_L+_ +8D/[6'P_\
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M?%-G(RA;FPUBVNX6>.X1V_HYT;0]/T:V2WLH4C*QJ&* '>1@D CJ 02<@=\
MC(KR^/N,,HRKZ[P]P]-JC"M*-#EFV\/2BO9QIQGRKG7N[JR;W47OQ<,\$XK%
MXUYKBXRE&%=**J=8M1JZ7DW:\M&UUOH?EY^W7\ _B!X(_9C^(&L_LI?#W2/%
M/Q*\+^&-3U#PQX$O;^?3=.U^^C4/-_:$T+++>6MC:>?JTNBQ.ESKYT]='T^6
M'4KZSN(?\[[XE?LO?M&?$SQ%XA^-WQ3\?:5\6_$_BM[_ %#5==G-[:7R2Z4K
M6]GX?CTF2WMV\*Z;I$L3Z;X=^'D5O;Z=X!L;%].TVTM[S4M<N-2_UE[J)I8F
M0PB7S&C1HVP!L:5 [ABKC=%%OFCROS2QJ@.6%?S[_P#!1+_@GG:Z1K?B']H[
MX/\ AA)]"\07%SJGQP\ 6T)V2F*,-;_$CPCIEI )(]?\L,GBK3(X4\^.6;5I
MABV9E^;\,>,\%P_C<UAF\:$*V:X:G1H9S5A'$XFA/W_W$:-5.GR1YG&,O:1=
MIRT5]?O>+,HQ&+PE". KU*-.E&G&I0I4HM2Y/BE*7-%^]IS*UO=3U:1_-+_P
M1V_X**?$3]@3XGIX*\7W&KZK\ /&VO06GCSPC<3RR7/A77;V"2WA\4:''* \
M*6CSL^H1A0UU%%;J,^02O^A1X-\7>"_BSX)TKQ-X:U/3_%7A'Q/IL%WIVIVC
MI)9W]M-$&)4(SF&XCWA+F$E6288*J!M'\#?Q[_8WED9/B)X$MX[P&U^WRO:0
M/)!J]CY<,D3;85=5O+-99PQ!)#R '&TX_0?_ ()0?MW>)?V<M8L_A)\0M0U'
M4/A3KLPTZU%_*9;CPEJ\\C#[5^]95T^P!9EE:4HAD"[B2,UAXB4,)CL73S#"
M2A3Q4_8MSP\8157DIPC"JXQ:4)5(I3DH[2DU>229T\,0Q<,)]3D[0I1:Y9Z)
M.4G*6KZR<F_)G](?Q#_9;\!0W4OB?P_X<LDU)MS23[&+[MTC\CYB0-^<8&,M
MC&>?ENYM=0\.:H_E)%%&IFC:%';3X+::!))Q?WUUPYM[6VBDG=CA$BBD8LJH
M2OZO:3J^C>+-'T_5=(O(M1T?5K=;FTN(G1UFMWAC);>A*N""'+*2OSC'!6OQ
MB_X+8Z=XN^&/_!/W]ISXA_"@7]IXCA\$Z78W&JZ*L\VMZ/X<\1>,_#OAWQ[K
M&D0VR-*;[2_ ]_J=]:,@PL$6JW#&.*VF8>CX?<9<F*I\/YK6<H591PZJ5W+_
M &=-I+W9+E:BIMZR6J4;VE<^,XWX+J8J4<SPTY1G3;J552A&3NM[M335^5:V
MTN^UWZO\(_\ @I1^RM'KUEX(U7XV^&WGGU1=+36YVU&7P;'J@\F+[,?%Y@;0
M8)))W18'GEE$I>/9?QHRHGZN6LUO-;6]Q#*LD4\$4L+B3S-\<T?FQN',DC2!
MX\RK(SN2F7W-R:_RB?#W[0/BR3X:'X9;;>+PE-%87LEGYL)M?LDL0\ZZ@NK;
M$EK83)%;36UPS!&O-P1CQ7^A-_P19\8?$;Q__P $R_V7=6^*=YJ5]XP@\%:M
MH\6K:R;J75]1\.:7XF\0:;X"U/4IKI1<SW-[X"MM"OEN)\_;+2_MKU&>*YBD
M?TO%_@3+N'*>6Y_@<;&I3S*JW*E&%%)QJQ]I"M%TIW7M.9.=)QM%R]V32:/5
MX S+%SH5,MK5:LW3;IQJU(M2IJG[G*HMM/E4='=72U7?WG]I?]F_QS^T?I][
MX1F^/?BOX<?#K5K0Z;XD\ >'_!/A[5+?7HY+HLZZKKUW=+?O9742H7L[6.*)
M!Q*6<$MX'\$O^"=_C7]G^]N6^%_[4OQ!\-V.L:KH.H>*]);X:^#[^QU]=$\N
M%H+J;6-2U&[L$OX$>$7FF3_:X89/,7,B)7ZT(054CH5!'T(!IU?GV!\0N,,M
MX?K\+8'-<'1X>Q7*\1EKX9X1J4ZTHJ2C.K7J</SQ52K'F;C7JUYUXR49JJIK
MG7E9WX&>&O$G%V%XZS_AZ>/XLR^"HY;G-/B/C;!8G X:-7&UEAZ,<+Q=3HQI
M.IC)RE2C2IT9)2IRI2I35..&JRV\+&5Y;AXHDC9UC,C7$NU#YP0;23G!QN4Y
MSR",CXN_:L_92U_]J'3H/#M_\9/$/@SX>>9I=Y>^"].\#^$==%[K6B7D]S:Z
MK)XBUF%=?BD<LD*VMM?6D,>-Y9U+H_W;17SV59QF>29IA,WRO$QPF-P,Z=;"
M58T*%65#$T9PJ4<13]O3K4U.E4A&<%*E.*?EH_N^).$\AXLX?S'AG/,$\=E.
M;4:^%S'#5,3BJ<<7@\73G0Q>$J3PU?#5X4L3AZM6A4E0KT:L85'*G.%10G'X
M'^ G[-OQ!_9_^'-W\+=$^/\ XBU;PY:://IG@**_^&_A2SN/ -[>75QJ4VH)
M+:W[GQ4HN;B1EM=4,<>1AI0&VGP'PE_P3H\1>"OC'/\ 'S2_VF/&9^*6LZGJ
MUSJWB"3X3^"3;:R?$MI';:Q:OHXN[BUL(+BUM@CM D3*RQEI65I8YOUVHKZ&
MAX@\6X7%<1XW#YI"&*XLHXRAQ!.IE.0UZ>9TL=C*F-KT\30JY/*E.G*M4O*"
MC34Y1C5E:K&,H_"XOP.\.,=A.%<!B>'U/!\#8O!XW@^E'B#C>F^'\3@5&EA:
MV"J0XRIS56AA5/#4)SD_9TY*/+.G&5&M^4?[6W_!/*']I_XAZ-\6O#_Q.O?A
MUXSTO3-(T>XV^%[75;&^B\.W4]QI>I6MS&+#6-*U*UDN))&AM+R.RNEPD\91
M2&9X_P#^";EA\5O =UI/Q3^.'Q+^)?Q?G@L$T3XN>*X5^P>#TT[S&2P\/^ =
M&OM'\.:-I6L0%++Q,MFCWWB)H-,N]:N+N[TZTFC_ %?HJ\/XD\>X+ <.Y;@^
M)L32PG"M)T<AC/!97*KEE.M6E/&PP>(I9?A\1AZ..HU*V&Q.'I5X8>K1J*%6
MG6IP]E+GS3Z/_A+G.9\6YKFG"5+'8GCB$:/%,*^:9Y'"YS"E0A3H5\=@L)FV
M"P53,Z-2G2J1SB&%I9C.--4JE>2J59U/S,\*_L7>./!7P*U'X0:3^T9XVTO5
M_&5_>S?$'XAWOA*Q\87GB?2+G0['PS:>%])TCQ!K%ZGA31-(T+3[33M.:QE8
MQQ0&011RNS2<]^SW_P $_O%G[,^JW$OPR_:0\7VOA>]U#3)?$?A;5?AAX-U&
MQ\26FFJQ6T%Y+J0N; S+,Z/J$#"X", 48H-WZJ45A'CSBN&'SO 1S1++.(L5
M0QF;Y<\%E]7#8W$X?VOLZM:%?!UHN<'5FZ3C"#HW:I-)LZ_^(&^&']K<,9W'
MA>-#,^",OPF6<&XS"9]Q=A,1P_@L,DI87#U:7%$G6PV)Y8K$4*L.2JHQC5]J
MDE'Y+^/_ ,&O&/QO\&W'@/PS\5=:^$&DZQ%J=IXQ32?!_AOQC-XLT;4;8V$F
MB3S>(Y)6TJV9%:X$FD&WF_>"-I5,8:O$/V5_V-M3_94>]TSP_P#&CQ/XF\$:
ML;F[N? &N> O#UM:77B"7^S(K;7H]>.H7NJ1"PBLL165RQAF#,,HZ1;?TCHK
MFP7&/$F!X;Q_"%+,U+AS-L;3QV:Y94RS)*D,=7PZ?U*56K/*:E;FP<VI4:JJ
MNK&*Y$XI\R]7-_"W@[/.,<O\1,RRRKB..,GH0P>3YZ\^XNI++<O=13Q&$P^!
MPO$V%PL5BHITZTU%*I%OVM*OK?\ (3QW_P $YO$WQ+^)UC\9?&/[4OC>7XEZ
M,^D)HWB&P^%G@[2Y=,A\/ZA/J6C016=KJ+6=[%:K>F$SW.9)MC228=G4?3WQ
M7_9\^)/Q@^"=O\&M?^/&N6C7]@-.\>>/;#X;^$[:Z\=::6:06DNCI>_9_#KA
MPADGTU7DF<.2B"4D_;M%=N.\0N,,QJ</5,9FT*KX3J4'PXEE>34%E&'P]15Z
M>'POU7+</S1AB(QKP=?VT855SJFYMS?G9?X+^'V5KC6. R6M@X>(-3&XGBN.
M&XCXSIO-\;C:*H5<7B92XIJ_O/8\]+]RJ$O9U)TU4C!\I^>_[,'[(.N_LQZ-
MK?@O3OC'XF\;?#C7/MS2>#;SP7X<T)+._P!56&'5-5M_$.G7RZL\U_"9A(61
M7C:0SQE98U)^6_ '_!+CQ1\)?'&HZI\)/VH/&GPX\.WMK?:2_P#PB/@VPMO'
M'_")WE]-?#PVNOWFIWU@JV=Q-(VFZVVF2ZG;R1PW2HDS,]?M9154O$;C7#OB
M6I0SE.KQC3GAN)WBL%A<90SC"3Q,,4Z>*PM6FJ#K0J4X>RQ*CSP2:5-QY8P\
M[$?1_P#"C$T."L/5X7J1_P"(>5%6X.QE#B/C##YMD%3D<*E/+LVH\2TL=2P6
M(3DL7EM2I7P&+C.:KX>3G-S_ !P\:_\ !*WP5JOQ$\->-_AU\3?&?PTT^#3+
MCP]X]L;$/J^K^*-/U$2Q^([W_A*;V--?CU;XA6]Q<6OCXZC)JMAJ+W/VFUCA
MND%ROUY^T#^QY\*OVDO!^C>"?&6G76GW7@W3EL? WC'1KB:W\4>%66QBT^7R
MFE#Z=K&G7UM;P?;]&U:&YTR],5N]S;M);0E?M.BIQ/B#QCC,;DN98GB#,JN.
MX<5..1XMXF2Q&6QI4HT(4:-6,8SEA848*E3PE1U,/"+J)4VJM12Z<O\  CPF
MRS+.*\FPG ?#L<GXZFY\6Y+5P^/Q&1YG4<JE3ZUA,HQ.;5\%DN/G7J/%5\;E
M,,)4K8S_ &IQA7<JDOQP\"?\$\/C_P##C39?!/A_]N#XJ>'_ (3(S16/ACP]
MH&E6>M:;ITBO#/9:3JKI<MX>2Y>61Y(=!CMM/2-Y3#9JTBRK]T_#[]G?X5>!
MOA'-\$M!\)6MW\/]0T[4M.\2:9JMO)>3^*!K8D.N:EKUQ> 37NJ:I=22W<UY
MD317'[Z,HWE"+ZFHKESWC3B+B3$4\;F^+P\L=AL9''X/%Y?@,'E-6EC86<,9
M7GEM'"U,9BU*,9RKUJJE*:YDH2;D^SA#P9\/>!8-<.Y9F5.5/+ZF48&.;9[F
M?$6$RK*:\>3%9;E.7\05LUP>6X7%P?)B5@J5"K62@JE64:<(+\6],_X);^+?
MA?XVOO$'[-O[3_C_ .#6E7,9MFTT:2NL72:9Y_VBTT9[]KN-/$>EZ:Q(M+;7
MH)7M@%BB=8F-?;/P1_93A^%_BB]^(_C7XD^.OC;\8M4TN'0KSXE?$.:W>73]
M D=9KK0_!GAO2EM=$\$Z//,CO+'IT+WEQ<RS&ZNYK<QPK]ET5W<1>)/&W%F%
MP^$X@S; X^-&%.%3$1X;X8PF98M4U&,98W.<)DN'SO&S:C&\\7F=>;<8WFXQ
MC!9<*^"7AMP3CJ^-X6R/%Y-&K5K5Z678;B7BRIDN"JXBI4KXB6 R+&<18O)<
M$J^*KXG%5*>$RVC2]MB:\HPA[22/RZ_:U_X)[:/^T+\0],^,'@_X@:Y\)?BW
MI%OH<$6NZ=:G4X9Y- N(KG2M7L;A735=%\1:3;P+#9:AHU[:?:=N+_SCG.-\
M0_\ @GIK/Q2^'%OX1^)GQY\=?$3QE)KVG7T'Q$\8:392Z?X2T:*=AJFE>"/
M6CFST/0M>O[411W7B^[M[O4;AQ(D\ODL(Z_5ZBC#>)7'6$I</4Z.?3]IPI]4
MI<.XBKA,+7Q&58/ XK%XK!X+#UZU.IB/8X>6+J*FI8CE=_WD:E-4Z-+S\?\
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M%]_?:A<^+_%VIS^(M:TBUO95=]"\.SZB&MM"\/Q$$1:;8QQ,8RQ?S&V5]70
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MVW=N[?5MOU?1:'U,8*"C&F_9PBK<D%%1?FU9N]M-.A$^_P"4@9.5STXZY)Y
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MK]Y^\1MRKEMRV7+9<JM;2T5I%6M9+9670****!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )W/T'\VJ)/O#\?Y
M&BBKCM+_  G-4^)?XO\ (FHHHJ#H6R]%^04444#"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
